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ABSTRACT

Antimicrobial resistance is a growing threat to human health both worldwide and
in the United States. Most concerning is the emergence of multi-drug resistant (MDR)
bacterial pathogens, especially the ‘ESKAPE’ pathogens for which treatment options are
dwindling. To complicate the problem, approvals of antibiotic drugs are extremely low
and many research and development efforts in the pharmaceutical industry have ceased,
leaving little certainty that critical new antibiotics are nearing the clinic. New antibiotics
are needed to continue treating these evolving infections. In addition to antibiotics,
approaches that aim to inhibit or prevent antimicrobial resistance could be useful. Also,
studies that improve our understanding of bacterial pathophysiology could lead to new
therapies for infectious disease. Natural products, especially those from the microbial
world, have been invaluable as resources for new antibacterial compounds and as insights
into bacterial physiology. The goal of this dissertation is to find new ways to treat
resistant bacterial infections and learn more about the pathophysiology of these bacteria.
Investigations of natural products to find molecules able to be used as new antibiotics or
to modulate resistance and other parts of bacterial physiology are crucial aspects of the
included studies.
The first included study, which is reported in chapter two, details a chemical
investigation of a marine Pseudoalteromonas sp. Purification efforts of the microbial
metabolites were guided by testing against a resistance nodulation of cell division model
of efflux pumps expressed in E. coli. These pumps play an important role in the
resistance of MDR Gram negative pathogens such as Pseudomonas aeruginosa and

Enterobacteriaceae. Through this process, 3,4-dibromopyrrole-2,5-dione was identified
as a potent inhibitor of the RND efflux pumps and showed synergistic effects against the
E. coli strain with common antibiotics including fluoroquinolones, beta-lactams,
tetracyclines, aminoglycosides, and chloramphenicol. The efflux pump inhibitory
mechanism was further proved through an accumulation assay with the Hoechst dye
33342.
In chapter three, we report the discovery of a 1,2-benzisoxazole with new
antibacterial activity against MDR A. baumannii, a pathogen with a critical need of new
treatments. This compound was produced by bacterial fermentation and synthetic
preparation and shows minimum inhibitory concentrations as low as 6.25 μg/mL against
a panel of four clinically relevant A. baumannii strains. Key structure activity
relationships were demonstrated using synthetic analogs of the lead 1,2-benzisoxazole.
We advocate for further studies to advance the development of this compound.
The third study, describes an in vitro quiescent state of uropathogenic E. coli
(UPEC) and bacteria-produced signals that can prevent this state. Quiescence was seen
in the classic UPEC strain CFT073 only when grown on glucose M9 minimal medium
agar plates seeded with ≤106 CFU. Interestingly, this quiescent state is seen in ~80% of
E. coli phylogenetic group B2 multilocus sequence type 73 strains, as well as 22.5% of
randomly selected UPEC strains isolated from community acquired urinary tract
infections in Denmark. Furthermore, it was determined that CFT073 forms a high
persister cell fraction under these growth conditions. Both the persistent and quiescent
states were inhibited significantly by a cocktail of lysine, tyrosine, and methionine at
concentrations relevant to those in human urine. The use of CFT073 mini-Tn5 metabolic

mutants (gnd, gdhA, pykF, sdhA, and zwf) showed that both quiescence and persistence
require a complete TCA cycle, but that the dormant states differ in that persistence
requires a non-functional rpoS gene and quiescence does not. These results suggest that
interference with these central metabolic pathways may be able to mitigate UPEC
infections.
In the fifth chapter, cranberry oligosaccharides and related compounds were
determined to be able to reduce the quiescent and persistent phenotypes of UPEC
CFT073. This is the first report describing components of cranberry juice with the ability
to modulate these important physiological aspects of UPEC and further suggests that
cranberry oligosaccharides may be vital to the effectiveness of cranberry juice products in
urinary tract infections.
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PREFACE
This dissertation has been written in the manuscript format as directed by the
guidelines set forth by the Graduate School of the University of Rhode Island.
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CHAPTER 1
Introduction
Bacterial infections and the post-antibiotic era
Infectious disease remains a significant threat to human health in the United
States and worldwide. In 2010, 117,716 deaths were attributed to infections of bacterial,
viral, or parasitic origins in the US.1 As a category, this ranks infectious disease as the
fourth most deadly form of illness behind only cardiovascular disease, cancer, and
respiratory disease, and ahead of diabetes and Alzheimer’s disease. Worldwide,
infectious disease has an even larger impact, accounting for 10 million deaths in 2011.2
This ranks it as the second most lethal disease category behind only cardiovascular
disease.2 A growing concern in the treatment of infectious disease is the drastic increase
in antimicrobial resistance. This is present in bacteria, viruses, and fungi, and is
complicating the treatment of infectious disease considerably. In fact, certain pathogenic
bacteria now exist that are resistant to nearly all treatment options, forecasting the socalled ‘post-antibiotic era.’3-6 The problem of antimicrobial resistance is immense with an
estimated 700,000 deaths worldwide each year, and these numbers are increasing.4 It is
estimated that in 2050 there will be 10 million deaths due to antimicrobial resistance
globally in a single year.4, 7 These deaths would lead to an estimated net loss of 100
trillion dollars of economic output.4, 7 Deaths due to infections are not the only clinical
consequence of a post-antibiotic era. Surgery, chemotherapy, and organ transplantation
rely heavily on antibiotics to facilitate their success.4, 7 Continuing on the trend of
increasing antimicrobial resistance would lead to a catastrophic change in lifestyle both
economically and medically.
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Among the most threatening problems in antimicrobial resistance are bacterial
infections involving multi-drug-resistant (MDR) pathogens. These are especially a
problem in the United States, where 23,000 people die each year due to MDR bacterial
infections.3 This is an especially common problem in the hospital setting where
antimicrobial resistance is difficult to eradicate and is seen in common nosocomial
pathogens.8 These pathogens that have been identified as high priorities for research are
referred to as ‘ESKAPE’ pathogens (Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter species).9 These organisms are in general difficult to treat and can cause
significant morbidity and mortality.9, 10 With the exclusion of E. faecium and S. aureus,
the ESKAPE pathogens are Gram-negative bacteria. This is important because there are
in general fewer treatment options for Gram-negative bacteria and developing antibiotics
against these bacteria has been historically less successful.11 The World Health
Organization recently released a ranking of highest priority bacteria for antibiotic
development, and all three critically important organisms are MDR Gram negative
bacteria.12
A major reason that the problem of antimicrobial resistance is increasing is the
dearth of new antibiotics being approved or researched. Since 1998, only four systemic
antibiotics (linezolid, daptomycin, tigecycline, and telavancin) have been approved that
have novel mechanisms of action.10 To combat this issue, antibiotic stewardship
programs can help, but long term solutions exist in the drug development arena. In 2010,
the Infectious Disease Society of America (IDSA) launched a campaign known as the
“10 x ’20 Initiative” that called for the development 10 new antibiotics approved by
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2020.10 Currently we are falling well short of the goal, with only four new antibiotics
being approved since the initiative and none of these with activity against the important
Gram-negative bacteria.13 Additionally, the current pipeline of antibiotics contains only
five drugs in phase II or III development with target indications of MDR Gram negative
infections.13 There is a clear void in the future treatment of infectious disease especially
for MDR bacterial infections, and without changes to the current course, a post-antibiotic
era is likely.

Bacterial mechanisms of resistance
Bacteria have developed mechanisms to avoid the toxic effects of antibiotics,
causing resistance. Inhibiting or circumventing these biological functions can restore the
activity of the antibacterial drug. Understanding the mechanisms of resistance is crucial
to developing agents that can restore the potency of antibiotics, especially in ESKAPE
pathogens and Gram-negative bacteria. Resistance mechanisms fall into these general
categories: drug alteration/inactivation, reduced drug intracellular accumulation, binding
site modification, and biofilm formation.8
Drug altering or inactivating enzymes are well studied and therapies have been
developed that can inhibit these enzymes. A well-studied example is the β-lactamase type
enzymes which are capable of inactivating β-lactam antibiotics such as penicillins,
cephalosporins, monobactams, and carbapenems.14 These enzymes have been the targets
of β-lactamase inhibitor drugs such as clavulanic acid, tazobactam, and sulbactam, all of
which are used in combination with β-lactam antibiotics to successfully treat bacteria that
produce β-lactamases.15, 16 While these approaches have been successful, the emergence
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of extended spectrum β-lactamases (ESBLs) such as New Delhi β-lactamase (NDM-1)
and oxacillin hydrolyzing enzymes (OXA) that are resistant to β-lactamase inhibitors and
confer resistance to most β-lactams is concerning.15, 17, 18
When bacteria are able to reduce the intracellular concentration of antibiotics, this
is frequently due to reduced production of channels that transport antibiotics into the cell,
or the up-regulation of efflux pumps able to eject antibiotics.8 Efflux pumps expel
antibiotics from the bacterial cytoplasm before they can reach their site of action.19, 20
These pumps can expel a broad range of substrates by coupling the efflux with a proton
or other ion.21 Certain efflux pumps, such as the resistance nodulation cell division
(RND) family pump AcrAB, have been suggested as biomarkers for the MDR phenotype
since they confer resistance to ≥ 5 antibiotics.22 Efflux pumps also contribute to the
resistance present in the ESKAPE pathogens.23, 24 The ability to inhibit efflux pumps with
a drug adjuvant to antibacterial therapy could help overcome resistance and treatment
failures. There has been progress in identifying efflux pump inhibitors (EPIs) of Grampositive pathogens such as S. aureus, but there is a sizable knowledge gap for Gramnegative efflux pumps.24 Discovery of EPIs for Gram-negative bacteria is greatly needed
to help supplement the already bare pipeline of new therapies for these problematic
pathogens.

Persistence and quiescence of bacterial pathogens
The phenomenon of bacterial persistence is a rapidly expanding research area in
the field of antibiotic development. Similar to resistance, bacterial persistence makes the
treatment of infections much more difficult. Persistence is characterized by dormant
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bacterial cells (persister cells) that are highly tolerant to antibiotics.25 When these cells
are isolated, re-cultured, and tested for antibiotic susceptibility, they show full
susceptibility, indicating these are not resistant mutants. In contrast, antibiotic resistant
bacteria will show a decrease in antibiotic susceptibility (require higher concentrations of
antibiotics to inhibit the growth of the bacteria). Persister cells are implicated as the
causative phenotype in chronic infections such as recurrent urinary tract infections
(UTIs), infections in cystic fibrosis, and tuberculosis.26-28 In addition to chronic
infections, persister cells are commonly associated with biofilms, which can allow them
to evade the immune system as well as exhibit antibiotic tolerance, causing antibiotic
treatment failures.25, 26, 28
Uropathogenic E. coli (UPEC) is an ideal organism to study persistence. 85% of
all UTIs are caused by UPEC and reinfection is common.29 Studies have shown that
UPEC are able to invade bladder and kidney epithelial cells during a UTI.30, 31 Following
invasion, the UPEC can either establish an intracellular bacterial community that evades
host immune defenses (in acute infection) or a quiescent intracellular reservoir (for
recurrent infections).31 The quiescent intracellular reservoir can remain viable for months
and cause reinfection following exfoliation of UPEC containing epithelial cells. Drugs
capable of inhibiting persistence and thereby inhibiting reinfection would be valuable
tools in the treatment of UTIs caused by UPEC. Additionally, compounds that reduce
persistence in UPEC could help identify targets and mechanisms necessary for persister
cell formation in other important bacterial pathogens. This could lead to new drugs and
improved treatment outcomes in challenging bacterial infections.
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Natural products as drug leads and antibiotics
Natural products represent both a classical source of drug molecules and a
promising future resource of novel medicines.32, 33 From the years of 1981-2014, 1211
small molecule drugs were approved for use, and of those 791 (64%) were either natural
products or inspired by natural products.32 More importantly, 59% of all drugs approved
to treat bacterial infections were naturally derived or inspired.32 The fraction increases to
74% when you exclude vaccines and look at only small molecule drugs (e.g., antibiotics),
indicating that natural products are by far the most significant source of antibiotics
available. Of the 12 major classes of antibiotics, nine of these, including β-lactams,
macrolides, tetracyclines, aminoglycosides, glycopeptides, and lipopeptides, contain a
natural product derived structure.34
Microorganisms have also been prolific producers of antibacterial compounds. It
is estimated that 16,500 antibiotic secondary metabolites have been discovered from
microorganisms and roughly 12,000 of those have antibacterial effects.35 While this
seems like a vast amount of compounds, genome sequencing has revealed that many of
the biosynthetic gene clusters are dormant under laboratory conditions, potentially
indicating that we have only scratched the surface of antibiotic compounds from
microorganisms.35, 36 An additional resource is the many ‘unculturable’ species. It is
estimated that upwards of 90% of all terrestrial microorganisms, and >99% of all aquatic
microorganisms do not grow under normal laboratory conditions.35, 37 The amount of
species diversity yet unstudied is vast, and we are now developing techniques to culture
these ‘unculturable’ microorganisms.37, 38 It is clear that the most prolific producers of
antibiotics, microorganisms, are still largely unstudied and could yield thousands more
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antibiotics as yet undiscovered. With the current shortcomings in the development of
new anti-infective agents, additional investigations of natural products, especially those
from microorganisms should be pursued.

Marine microorganisms as sources of bioactive natural products
There is significant data to suggest the promise of marine organisms as potential
sources of bioactive compounds, including antibiotics. In a marine environment, an
average of 106 bacterial cells and 103 fungal cells exist per milliliter of seawater which
creates a constant and mobile threat of infection to macroorganisms, as well as
competition between microorganisms for survival.34 Investigations of marine organisms
have uncovered compounds in diverse classes of secondary metabolites (ribosomal
peptides, non-ribosomal peptides, polyketides, alkaloids, and terpenes) that possess
potent bioactivities.34 Marine sediments also harbor vast microbial diversity (108 cells in
a gram of wet sediment) that has been largely unstudied.34, 39 Compared to terrestrial
studies, the search for antibiotics from the marine environment is still in its infancy.34
The marine environment comprises a vital resource of biodiversity that should be further
explored for new antibiotics.
Natural products discovered from the marine environment span a large variety of
organisms, but microorganisms show significant potential. Because terrestrial
microorganisms have been such a significant source of antibacterial compounds, it stands
to reason that marine microorganisms would also be prolific producers of bioactive
molecules. 491 (42%) of the new compounds isolated from the marine environment in
2013 were isolated from microorganisms indicating they are already a major source of
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marine chemistry.40 These compounds exhibit diverse bioactivities including
antibacterial, anticancer/cytotoxic, anti-quorum sensing, antiviral, anti-inflammatory,
immunosuppressant, antiprotozoal, and antifungal.40-42 Some antibacterials discovered
from marine microorganisms include non-ribosomal peptides (bogorol A, emericellamide
A, and thiocoraline), polyketides (abyssomycin C and pestalone), and alkaloids
(marinopyrrrole A).34 Additionally, while the macroorganisms such as sponges, algae,
and tunicates represent a significant source of chemistry, it is proposed that
microorganisms acting in symbiotic relationships are responsible for at least a portion of
the identified novel chemistry.43, 44 There are currently 20 drugs (molecules in clinical
trials or approved by the FDA) either isolated from a marine source or inspired by marine
chemistry.45 It has been proposed that 17 are produced by microorganisms associated
with the macroorganisms from which those drugs were originally isolated.45 Thus, marine
microorganisms show significant potential as a resource for new antibacterial and other
bioactivities that might be useful in the future treatment of drug resistant bacterial
infections.
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ABSTRACT
Members of the Resistance Nodulation Cell Division (RND) of efflux pumps play
essential roles in multidrug resistance (MDR) in Gram-negative bacteria. Herein, we
describe the search for new small molecules from marine microbial extracts to block
efflux and thus restore antibiotic susceptibility in MDR bacterial strains. We report the
isolation of 3,4-dibromopyrrole-2,5-dione, an inhibitor of RND transporters from
Enterobacteriaceae and Pseudomonas aeruginosa, from the marine bacterium,
Pseudoalteromonas piscicida. 3,4-Dibromopyrrole-2,5-dione decreased the MICs of two
fluoroquinolones, an aminoglycoside, a macrolide, a beta-lactam, tetracycline, and
chloramphenicol between 2 and 16-fold in strains overexpressing three archetype RND
transporters (AcrAB-TolC, MexAB-OprM, and MexXY-OprM). 3,4-Dibromopyrrole2,5-dione also increased the intracellular accumulation of Hoechst 33342, in wild-type,
but not in transporter deficient strains; and prevented H33342 efflux (IC50 = 0.79 µg/mL
or 3 µM), a hallmark of efflux pump inhibitor (EPI) functionality. A metabolomic survey
of 36 Pseudoalteromonas isolates mapped the presence of primarily brominated
metabolites only within the P. piscicida phylogenetic clade where a majority of antibiotic
activity was also observed, suggesting a link between halogenation and enhanced
secondary metabolite biosynthetic potential. In sum, 3,4-dibromopyrrole-2,5-dione is a
potent EPI and deserves further attention as an adjuvant to enhance the effectiveness of
existing antibiotics.
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The emergence of multidrug resistant (MDR) Gram-negative pathogens, including
Enterobacteriaceae and Pseudomonas aeruginosa, has become a substantial threat to
treating infectious disease. Twenty percent of all deaths globally are the result of bacterial
infections,1 and hospital-acquired infections are the sixth leading cause of mortality in the
U.S.,2 with 23,000 deaths per year due to MDR infections in the U.S. alone.3 The rapid
decline in antibiotic effectiveness has led some clinicians to estimate the future utility of
available antibiotics to be limited to a few years, in some cases, against MDR strains.4
Developing tools to battle these emerging MDR Gram-negative pathogens deserves
priority status,5 as they now account for nearly 70% of infections in intensive care units
in the U.S.2 Alarmingly, many Gram-negative clinical strains are becoming resistant to
nearly all antibiotics including aminoglycosides, cephalosporins, fluoroquinolones and
carbapenems,3 leaving few antibiotics in the therapeutic repertoire to treat these
infections.6-8 In the search for new antimicrobials, random screening of libraries of
synthetic or natural products are estimated to have a primary hit-rate of up to 1,000-fold
lower against Gram-negative than for Gram-positive bacteria.9 Of the antibiotics
approved by the FDA from 1998 to 2005, including those in clinical trials, and various
stages of preclinical development, most lack appropriate activity against any Gramnegative bacteria.6, 7 Making incremental improvements to the chemical scaffolds of
existing antibiotics is at best a short-term strategy for the impelling need for both new
drugs and novel approaches to combat multidrug resistant pathogens.10 Consequently,
developing compounds targeting the resistance mechanisms themselves is warranted (e.g.
the clinically proven beta-lactam/beta-lactamase inhibitor cocktail, amoxicillin/clavulanic
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acid),4 thereby i) obviating the emergence of resistance, and ii) regaining antibiotic
potency.
The rapid spread of resistance is, in part, a result of constitutive over-expression of
transmembrane efflux pumps that expel antibiotics before they can reach their
intracellular target.11 Members of the Resistance Nodulation Cell Division (RND)
superfamily of MDR pumps have been implicated in the high intrinsic resistance of
Gram-negative species,12, 13 whose tripartite RND pumps recognize and expel a broad
range of substrates (including antibiotics, charged and neutral molecules, organic
solvents, lipids, bile salts, and quorum signal molecules),9 via a coupled exchange with
protons or ions.14 Permanent overexpression of RND pumps leads to multidrug resistance
in bacteria,15 while their deletion restores antibiotic susceptibility16 further confirming
this transporter is an important therapeutic target. Polyspecificity of RND pumps is
central to the emergence and spreading of efflux-mediated resistance, as these pumps
subsequently allow for acquisition of additional resistance mechanisms,9, 17 and have a
significant role in bacterial pathogenicity/virulence, invasion, adherence and host
colonization.14 In drug resistant Escherichia coli, Salmonella enterica, Enterobacter
aerogenes, and Klebsiella pneumoniae, overproduction of AcrAB-TolC pump and its
homologue MexAB-OprM/MexXY-OprM in Pseudomonas aeruginosa are the main
RND archetypes reported in clinical isolates.11, 17, 18 RND transporters are found in both
prokaryotes and eukaryotes; however, homology between bacterial and human RND
proteins is negligibly low (16% identity), suggesting minimal overlap in RND transporter
substrate specificities. 7 In addition, clinical isolates with more resistant MDR phenotypes
(resistant to ≥5 antibiotics, including 100% fluoroquinolone resistance), are more likely
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to overexpress the RND pump, AcrAB, suggesting this RND pump maybe a biomarker of
MDR,19 making these efflux pumps “key” targets for the development of an efflux pump
inhibitor (EPI) as an adjuvant to existing antibiotics.20
Our search for small molecule EPIs from the microbial realm has been aided by the fact
that natural products have often been selected precisely for their ability to penetrate both
outer and inner membranes of Gram-negative bacteria.21 A countermeasure by antibioticproducing microbes is to co-evolve inhibitors of their competitor’s resistance
mechanisms to enhance the efficacy of their own antibiotics,21 exemplified by the
Streptomyces spp. producing both beta-lactam antibiotics and the beta-lactamase inhibitor
clavulanic acid. 22 There is substantial evidence that marine bacteria produce cocktails of
both antibiotics to control surface colonization,23, 24 and nontoxic secondary metabolites
capable of quenching quorum sensing-controlled activities in other species.25 However, to
our knowledge no systematic study has screened for EPIs from marine microbial
exudates (i.e., compounds excreted into the extracellular medium) against RND pumps.
Regardless, our approach is validated by previous screening of terrestrially-derived
microbial fermentations which resulted in two new natural product EPIs targeting
MexAB-OprM from Streptomyces (EA-371α and EA-371δ) potentiating levofloxacin
minimum inhibitory concentrations (MICs) 4-fold and 8-fold, respectively.26 The
microbial EPI, MP-601,205 is currently used to treat P. aeruginosa respiratory infections
in cystic fibrosis patients.14 Thus far, a diverse set of natural product chemical scaffolds
(including polyphenols, flavones, flavonols, flavonolignans, flavonoids, diterpenes,
triterpenoids, oligosaccharide-glycosides, and pyridines) have been validated as EPIs in
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Gram-positive bacteria such as Staphylococcus aureus.27 A remaining challenge is the
discovery of EPIs targeted toward Gram-negative efflux pumps.27
We hypothesized that microorganisms obtained from the marine environment produce
EPIs as regulators of diverse ecological interactions, and as such present a unique bioprospecting opportunity. In the present paper our objectives were: (i) to screen our inhouse chemical library to identify marine microbial isolates capable of reducing
antibiotic MICs ≥4-fold in three strains overexpressing three archetype RND transporters
(AcrAB-TolC, MexAB-OprM, and MexXY-OprM) common in Gram-negative
pathogens, (ii) to isolate and chemically characterize the putative EPI lead, (iii) to
evaluate the potential of our lead molecule to potentiate the activity of various classes of
antibiotics, (iv) to quantify the inhibitory activity of this molecule in functional whole
cell accumulation and efflux assays, and (v) to compare the exo-metabolomic fingerprints
(i.e., the relative abundances of chemical features with unique m/z values and retention
times) of EPI-producing Pseudoalteromonas strains versus other related members of the
genus, thereby linking metabolite diversity with genetic relatedness. We report herein the
isolation, identification, and demonstration of EPI functionality of 3,4-dibromopyrrole2,5-dione, an inhibitor of RND transporters from Enterobacteriaceae and P. aeruginosa,
having been isolated from the marine bacterium, Pseudoalteromonas piscicida. Our paper
also demonstrates that the production of halogenated secondary metabolites is associated
with those Pseudoalteromonas clades harboring antibiotic compounds and EPIs; further
highlighting that marine microbial sources, especially marine Gram-negative bacteria,
represent a tractable source of new chemical scaffolds for EPI development.
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RESULTS AND DISCUSSION
Isolation and Identification of 3,4-Dibromopyrrole-2,5-dione. Crude exudate
extracts from a total of 1308 marine microbial isolates were screened in the pIodonitrotetrazolium chloride (INT) assay to assess MDR reversal potential. This initial
screening identified 36 marine microbial isolates of diverse phylogenetic affiliation
(2.8% hit rate) capable of potentiating (i.e., reducing the antibiotic MIC by at least 4-fold)
the activity of chloramphenicol and/or erythromycin when tested against E. coli MDR
strains AG102, MG1655 ΔBC/pABM, and MG1655 ΔBC/pXYM. Phylogenetic analysis
of 16S rRNA sequences indicated seven isolates of these 36 were Pseudoalteromonas sp.
(A197, A198, A256, A746, A754, A757, B126) (Figure S1, Table S1, Supporting
Information). Isolate B126 could not be revived from frozen culture; therefore it was
dropped from further analysis. Crude extracts displaying an initial positive hit in one or
more test E. coli strains in the bacterial susceptibility assay were prioritized for further
testing. The INT assay was performed in the presence and absence of antibiotic to
establish the MIC of the crude extract (tested in a serial dilution series) and determine if
EPI-like activity was present by examining the minimal effective concentration of the
crude extract required to potentiate the antibiotic MIC at least 4-fold. These experiments
indicated isolates A197, A198, and A256 produced antibiotics only, while A746, A754,
and A757 demonstrated EPI potential and antibiotic activity (data not shown). The
strongest EPI-like activity was seen for A757, therefore this isolate was chosen for
further study. Bioassay-guided fractionation of the crude extract generated from 16.5 L of
A757 exudates resulted in the isolation of 3,4-dibromopyrrole-2,5-dione. The structure of
3,4-dibromopyrrole-2,5-dione was established on the basis of NMR spectroscopic and
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LC-MS data in comparison with an authentic standard (Figure S2-6, Supporting
Information). To our knowledge, this paper represents the first description of 3,4dibromopyrrole-2,5-dione from a microbial source, although the original report of its
isolation from nature was from the marine sponge Axinella brevistyla collected in western
Japan, where it was reported to exert modest antifungal activity and cytotoxicity against
murine lymphocytic leukemia cells.28 However, since over 50% of a sponge’s biomass
can be attributed to microorganisms, it is conceivable that the origin of 3,4dibromopyrrole-2,5-dione may be from sponge-associated microorganisms.29
Antibiotic Potentiation Activity by 3,4-Dibromopyrrole-2,5-dione. The checker
board assay was used to determine whether 3,4-dibromopyrrole-2,5-dione potentiates the
activity of two fluoroquinolones (ciprofloxacin; CIP, and levofloxacin; LEV), an
aminoglycoside (kanamycin; KAN), a macrolide (erythromycin; ERY), two β-lactams
(oxacillin; OXA, and piperacillin; PIP), tetracycline (TET) and chloramphenicol (CHL),
known substrates for RND transporters, 17, 30-32 against our test strains of MDR E .coli.
The checkerboard method is so named due to the pattern of wells formed by dilutions of
the antibiotic and test compound being examined, at concentrations above, at, and below
their MICs. Interactions between 3,4-dibromopyrrole-2,5-dione and various antibiotics
were classified based upon the fractional inhibitory concentration index (FICI), where
FIC of < 0.5 is synergistic, and indicative of the presence of an EPI; 0.5-1 is indifferent;
and >1 is antagonistic. The results, shown in Table 1, demonstrate 3,4-dibromopyrrole2,5-dione decreases the MICs of various antibiotic classes between 2 and 16-fold, with
corresponding fractional inhibitory concentration indices (FICI) indicating synergistic
activity of 3,4-dibromopyrrole-2,5-dione with all antibiotics tested with the exception of
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piperacillin. 3,4-Dibromopyrrole-2,5-dione exhibited antibacterial activity at
concentrations >100 µg/mL for all three E. coli strains overexpressing efflux pumps. The
greatest decrease in antibiotic MICs was seen for erythromycin, where 3,4dibromopyrrole-2,5-dione decreased the antibiotic MICs between 8 and 16-fold.
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Table 1. 3,4-dibromopyrrole-2,5-dione potentiates the antibacterial activity of various classes of antibiotics against E.coli strains that over-express efflux pumps.
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Hoechst 33342 Accumulation and Efflux Inhibition. To verify that inhibition of
efflux, and not membrane permeabilization, is the mechanism by which 3,4dibromopyrrole-2,5-dione potentiates antibacterial activity, we determined whether 3,4dibromopyrrole-2,5-dione was capable of causing the accumulation of the fluorescent
efflux pump substrate (Hoechst 33342) in the wild-type, E. coli AG100 expressing the
AcrAB-TolC pump; and conversely confirm the E. coli mutant AG100A lacking the
pump would not be affected. Upon entering the bacterial cell, H33342 becomes
fluorescent once bound to the DNA minor groove. As shown in Figure 1A, addition of
3,4-dibromopyrrole-2,5-dione at concentrations ranging from 0.06 – 64 µg/mL, resulted
in a dose-dependent increase in intracellular H33342 fluorescence, consistent with an EPI
effect. Concentrations of 3,4-dibromopyrrole-2,5-dione ≥ 1 µg/mL were equal to or more
effective than the reference inhibitor PAβN (15.6 µg/mL) in causing H33342
accumulation. We reasoned that antibiotic-sensitive mutant E. coli (AG100A), lacking
the target RND pump of 3,4-dibromopyrrole-2,5-dione would not be affected by the
compound. Results displayed in Figure 1B, show there is no effect of 3,4dibromopyrrole-2,5-dione on H33342 fluorescence in AG100A, which is consistent with
the hypothesis that RND pumps are the target of 3,4-dibromopyrrole-2,5-dione and
indicates MDR reversal is limited to efflux pump expressing E. coli strains. In addition, if
the mechanism of action of 3,4-dibromopyrrole-2,5-dione was via membrane
permeabilization, we would have seen a dose-dependent increase in H33342
accumulation regardless of test bacterial strain, which we did not observe.
Demonstration of efflux activity in AG100 requires that accumulation of H33342 has
taken place. Following H33342 “loading”, monitoring of efflux was initiated in the
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presence of increasing concentrations of 3,4-dibromopyrrole-2,5-dione (0.06 – 64
µg/mL) in medium containing glucose at 37oC. The near complete inhibition of H33342
efflux was observed in comparison to control wells (Figure 1C) indicating efflux
competent bacterial cells were not capable of transporting H33342 in the presence of 3,4dibromopyrrole-2,5-dione. Concentrations of 3,4-dibromopyrrole-2,5-dione as dilute as
0.06 µg/mL showed significant (p < 0.05) H33342 efflux inhibition in comparison to
solvent controls (Table 2). The IC50 value for 3,4-dibromopyrrole-2,5-dione in the efflux
assay was calculated to be 0.79 µg/mL or 3 µM. A comparison of bacterial RND pump
EPIs reveals that compounds, including 3,4-dibromopyrrole-2,5-dione, contain
hydrophobic ring systems that presumably interact with hydrophobic residues located
near or in the substrate binding site.33
Table 2. Hoechst 33342 accumulation and efflux of in the presence of 3,4dibromopyrrole-2,5-dione
Accumulation

Efflux

Compound
(µg/mL)

AG100

DBDP

Mean (RFU)

S.D.

Mean (RFU)

S.D.

Mean (RFU)

S.D.

64

1208***

20

1090

10

-68***

54

16

1165***

8
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14

-34***

58

4

1130***

11

1175

8

-101***

34

1

1006***

4

1065

5

-247***

30

0.25

796***

12

1003

17

-351***

7

0.063

758

9

1016

15

-422*

37

Hoechst only

746

16

1038

10

-472

13

a

a

AG100A

b

AG100

a

AG100, wild-type E. coli K-12 strain
AG100A, ΔacrAB mutant
Final mean values from last four minutes of the assay, compared using a one-way ANOVA
with Dunnett's multiple comparison test comparing treatment versus Hoechst H33342
control. The level of significance is indicated by asterisks (***p<0.0001,*p<0.05, n=8)
IC50 value calculated from efflux data was 0.79 µg/mL or 3µM (95% confidence interval
0.69-0.91 µg/mL).
b
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3,4-Dibromopyrrole-2,5-dione also is known to react with disulfide linkages in the
presence of a strong reducing agent such as (tris(2-carboxyethyl)phosphine).34 It is
conceivable, but unlikely, that 3,4-dibromopyrrole-2,5-dione is displacing and
coordinating certain accessible, reduced disulfide linkages in the RND pumps and
permanently modifying their conformation by this crosslinking type displacement;
however, the lack of antibiotic activity and range of pharmacokinetics argue against this
type of action. Although the subject of another study, experiments employing
halogenated and non-halogenated maleimides will be informative in terms of mode of
action.
Chemophylogenetic Analysis of Extracts from Pseudoalteromonas Isolates.
Analysis of our untargeted -HRESI metabolomics comparison indicated the presence of
many halogenated features, the distributions of which differed greatly across
Pseudoalteromonas clades (Figure 2B and 2C, Figure S7, Table S2, Supporting
Information). Principle component analysis (PCA) of -HRESI mode data (n = 1112
chemical features present in Pseudoalteromonas samples at concentrations 10x those in
the media only blank) revealed that most Pseudoalteromonas clades were chemically
similar overall with the exception of two clades, IV and VI, which were distinguishable
from the other clades based on the first two principal components of a four component
model (capturing > 60% of the total variance) (Figure 2B). Of the two clades
distinguishable via PCA, Clade IV contained the EPI producing strain A757 and two
additional strains with EPI activity based on dilution series testing (A746 and A754),
while Clade VI contained two strains (A197 and A198) with antibacterial activity only
(Table S1, Supporting Information). In summary, the PCA analysis of -HRESI data
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revealed those strains with the most disparate chemistry (designated by Clades IV and
VI), corresponded to the majority of strains with antibiotic activity against MDR E. coli.
In order to discern which chemical features were unique to Clade IV (and
subsequently strain A757), we examined chemical feature loadings on the first principal
component. It is important to note that great care must be taken to avoid the assumption
that any of these features alone would be significantly differentially produced by
Pseudoalteromonas strains,35 however, examining the loadings is still useful and will
likely reveal suites of compounds with varying concentrations in different
Pseudoalteromonas extracts. Of the 1112 features, 221 chemical features had small
negative loadings (<-0.02) within the first principal component and highly positive
loadings (>0.02) on the second principal component (Figure S7, Supporting Information),
and were therefore likely candidates to distinguish Clade IV from the remaining clades
(Figure 2B). Further analysis of these 221 features indicated that i) several shared
retention times, and ii) had masses ~2 amu apart, suggesting that many chemical features
were isotopes of halogenated metabolites. We determined that of these 221 features, 129
were isotopes of 46 individual brominated metabolites based upon both isotopic
distribution and shared retention time (Table S2, Figures S8-30, Supporting Information).
Of the 46 halogenated metabolites found, all were exclusively produced by members of
Clade IV (Figure 2C), demonstrating that there is a distinct Pseudoalteromonas
chemotype characterized by halogenation of the exo-metabolome. Moreover, this
“halogenome” appears to be dominated by brominated metabolites, with only some
metabolites (<10) that are additionally chlorinated (Table S2, Supporting Information). In
addition, we observed several other brominated compounds (~30-40) based upon isotopic
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signatures produced by A757 that were not accounted for in the initial 221 chemical
features (screened based on their loadings), suggesting that a large percentage of A757
exo-metabolome may be subject to halogenation (Tables S2 and S3, Supporting
Information). Relative concentrations of halogenated compounds from Clade IV appeared
different even within members of the same species (Figure 2C), indicative of intraspecies chemical diversity and further sub-clustering among isolates of the same species
(A757, A754, A746 and B149) a phenomenon previously described for P. luteoviolacea
strains.36 Taken together, these results indicate that the production of halogenated
compounds could be a biomarker for marine isolates with enhanced biosynthetic
potential. Of the four strains in our culture collection designated as belonging to Clade
IV, A757 and A754 produced all 46 metabolites, whereas strains A746 and B149
produced only select halogenated metabolites, including 2,3,4,5-tetrabromopyrrole, a
known weak antibiotic from Pseudoalteromonas spp.,37 (Figure 2C). 2,3,4,5Tetrabromopyrrole appears to be the most abundant brominated compound we observed
(retention time 20.8 min, major ion m/z 381.6722, Figure 2C, Table S2, Supporting
Information) and present in all members of Clade IV. Because of the dominance of
2,3,4,5-tetrabromopyrrole in our samples and its shared carbon skeleton with 3,4dibromopyrrole-2,5-dione, we tested an authentic standard of 2,3,4,5-tetrabromopyrrole
in EPI functionality assays and determined 2,3,4,5-tetrabromopyrrole is not responsible
for the EPI activity of strain A757 (data not shown). We also determined the presence of
2,3,4-tribromopyrrole (retention time 20.1 min, major ion m/z 301.7639, Figure 2C, Table
S2, Supporting Information) present in A757, A754 and A746, but not in B149). 2,3,4-
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Tribromopyrrole is reported to be produced by P. luteoviolacea,38 found within Clade IV,
and is a known feeding deterrent in marine systems.39
The limit of detection of 3,4-dibromopyrrole-2,5-dione with an authentic standard was
established to be 11.1 ng/mL. Our yield from 16.5L of A757 culture was on the order of 1
mg/L of 3,4-dibromopyrrole-2,5-dione. 3,4-Dibromopyrrole-2,5-dione should have been
detected in our crude that was initially screened for antibiotic activity, however, we did
not see this ion until culture scale-up and further purification, suggesting ionization
masking effects from the presence of a complex mixture including 2,3,4,5tetrabromopyrrole, which was observed to co-elute with 3,4-dibromopyrrole-2,5-dione
under these chromatographic conditions. In addition to numerous halogenated
metabolites, we also were able to observe other unique metabolites produced by members
of Clade IV (versus other Pseudoalteromonas clades), when using PCA to compare
metabolomes generated with +HRESI data (n = 1552 chemical features; Figures S31, S32
and S33, Tables S4, S5 and S7, Supporting Information), although we did not follow up
with a complete characterization of these chemical features to avoid over-interpretation
of these data. Strain A746 was distinguished by a group of 177 chemical features
(Figures S31and S32, Table S4 Supporting Information) whereas other members of Clade
IV (strains A575, A574, B149) were more easily distinguished by a group of 56 chemical
features (Figure S31 and S33, Table S5, Supporting Information). Although we did not
seek to fully annotate chemical features detected in +HRESI, these data also indicate
(along with –HRESI results) that members of Clade IV do possess a characteristic exometabolome.
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Screening features detected with our untargeted metabolomics approach (both –HRES
and +HRES) against an in-house database containing previously reported
Pseudoalteromonas metabolites indicated isolates in our collection potentially produce
molecules previously described for Pseudoalteromonas spp. Molecular features
annotated in +/-HRESI mode data with isotopic distribution patterns and predicted
formulae matching these dereplicated compounds are shown in Figure 3 and Tables S8
and S9, Supporting Information. A potential annotation for the antibiotic, 2-n-heptyl-4quinolinol,40 known to also influence bacterium-phytoplankton interactions,23 was
exclusively found within members of Clade IV in both +HRESI and –HRESI data sets
(Figure 3). Previous work indicated bacterial production of 2-n-heptyl-4-quinolinol is
surface-dependent, and bacteria are able to generate localized zones of concentrated 2-nheptyl-4-quinolinol on sinking or suspended particles without loss of this antibiotic to the
surrounding seawater.23 It would be interesting to know if 3,4-dibromopyrrole-2,5-dione
has an overlapping accumulation profile as the putative 2-n-heptyl-4-quinolinol ion in
isolate A757. Moreover, features matching the predicted molecular ions for the antibiotic
diketopiperazine, cyclo-(L-phenylalanyl-4R-hydroxyl-L-proline)37 and the antifungal,
isatin (1H-indole-2,3-dione)41 were also noted in many isolates in both ionization modes
(Figure 3A & B). Clade IV may also exclusively produce the antibiotic, 2-n-pentylquinolinol40 (Figure 3A). Additional annotations for molecular ion matches from our
database include: the cryptic metabolite, 3-formyl-L-tyrosine-L-threonine dipeptide,42
three isomers of indole-3-carboxaldehyde,40 three isomers of the antibiotic, phydroxybenzaldehyde40 and two isomers of antibiotic, p-hydroxybenzoic acid,43 all of
which were expressed by the majority of Pseudoalteromonas isolates in our collection
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(Figure 3A). Molecular features found only in a single isolate include those matching to
the ions for the antifungal polyketide, alteramide B44 from A757; the
antistaphyloccoccal/antivibrio compound, indolmycin45 and Gram-negative antibiotic,
korormicin 1b46 from A345; and the diketopiperazine, cyclo-(D-pipecolinyl-Lisoleucine)47 from A198 (data not shown). Molecular ions matching the antibiotic
diketopiperazine cyclo-(L-pipecolinyl-L-phenylalanine)37 was found in A474 and A454,
while features matching the calculated [M+H]+ ions of antibiotic, pseudomonic acid C48
and the cytotoxic carboline alkaloid, norharman (9H-pyrido[3,4-b]indole)49 appeared to
be expressed in the majority of our isolates, with a few exceptions (Figure 3B). Future
work will be able to discern the true identities of these chemical features, as several
isomers are possible for each of the detected ions in our analysis. Regardless,
chemophylogenetic analysis indicated that some compounds were i) characteristic of a
particular isolate, ii) clade specific (e.g., halogenated species, 2-n-heptyl-4-quinolinol,
and 2-n-pentyl-quinolinol) or iii) ubiquitous in the majority of isolates.
Increasingly, non-photosynthetic Gram-negative bacteria (NPGNB) are being
recognized as the true source of pharmaceutically-relevant molecules from marine
macroorganisms;29 however, the difficulty in culturing marine-derived strains to
sufficient quantities has likely hampered intense bio-prospecting efforts.29 Indeed, the
majority (86%) of our marine isolates found to have MDR reversal activity in our initial
screening efforts fall within the NPGNB group, and have been isolated from both abiotic
and biotic surfaces (Table S1, Supporting Information). The cosmopolitan marine genus
Pseudoalteromonas (class Gammaproteobacteria), which constitute 0.5-6% of bacterial
species globally,50 has been found in seawater, marine sediments and epiphytically
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associated with marine eukaryotes, and has been a prolific source of brominated
compounds,37, 51, 52 including pentabromopseudilin,36 the first marine microbial natural
product to be described.53, 54 Compounds isolated from this genus function in multiple
ecological roles including their involvement in chemical protection, settlement,
germination and metamorphosis of marine invertebrate and algal species, as well as more
commercial uses as antifoulants, antibacterial, antifungal and cytotoxic agents.37, 52, 55
Recent genome mining work has uncovered the biosynthetic pathways responsible for
brominated pyrrole/phenol biosynthesis (bmp)38 indole derivatives, siderophores,
polyketides, homoserine lactones, peptides (both ribosomal and non-ribosomal origin)
and hybrid molecules,56 which likely represent just the tip of the iceberg, as the number
of pathways encoded in Pseudoalteromonas genomes eclipses the fraction of molecules
identified thus far.55
For marine bacteria, including many antibiotic producing Pseudoaltermonas spp.,37, 57
a viable strategy by these organisms may be to secrete an EPI to enhance their own
antibiotic effectiveness. Previous research suggests the dominance and enriched
diversity51 of Pseudoalteromonas spp. in biofilms could be attributed to their ability to
rapidly form microcolonies and produce extracellular antibacterial compounds.36, 58 The
production of EPIs targeting RND pumps and other MDR pumps may effectively disable
the antibiotic resistance mechanisms of competitors allowing Pseudoalteromonas strains
to colonize and persist in biofilms. This chemical strategy of using EPIs to enhance
antibiotic potency is not novel in nature; rather it has been previously described in plants
mounting an attack against surface-associated Gram-positive bacteria.59 A blastp search
of all 54 Pseudoalteromonas spp. genomes available in the IMG database
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(https://img.jgi.doe.gov/cgi-bin/w/main.cgi) showed amino acid identities to the inner
membrane RND transporters as high as 71% for AcrB, 65% for MexB and 52% for
MexY. Efflux pumps with homology to AcrB and MexB are known to be functional in
Vibrio parahaemolyticus inhabiting brackish saltwater, for example, where the VmeAB
efflux pumps have been shown in vitro to exhibit bile salt and antibiotic resistance
phenotypes.60 Although it is unclear what role, if any, the putative RND-type homologues
present in Pseudoalteromonas spp. may play, it is possible that they could be aiding in
moderating allelopathic interactions as was found with antibiotic resistance and
production in Vibrio spp. bacteria.61 Considering efflux pump inhibitors as antibiotic
adjuvants among natural populations could add a new dimension to our understanding of
competition between microbial populations. Our data show that Pseudoalteromonas
strains indeed display niche specificity in regards to halogenated metabolite production,
and further bioprospecting efforts could benefit from a focus on environments - such as
biofilms, to enhance discovery of new antibiotic and EPI therapeutics.
EXPERIMENTAL SECTION
General Experimental Procedures. Nuclear magnetic resonance (NMR) spectra (1D
1

H and 13C) were recorded on a Bruker Avance III 300 MHz spectrometer in DMSO-d6

with the solvent (δH at 2.54, δC at 39.5) used as an internal standard. Chemical shifts are
given as δ (ppm). HPLC-MS experiments were accomplished using an Agilent
Technologies 6230 ToF with Dual Agilent Jet Stream Electrospray Ionization source,
equipped with an Agilent 1260 Infinity series HPLC with a Phenomenex Kinetex™ 2.6
µm, C18, 100 Å, LC column (150 x 2.1 mm) as the stationary phase. All HPLC-MS
experiments used a flow rate of 0.2 mL/min. This instrument was also equipped with

35
Agilent Mass Hunter Workstation version B0.4.00 software. Mass spectra peak picking
and alignment software MZmine 2.1162 was used for processing mass spectra before
principal component analysis with the PLS Toolbox in Matlab version 8.2.0.7. EPI
isolation was accomplished using vacuum liquid chromatography (10 x 5 cm) with Silica
gel, pore size 60 Å, particle size 40-75 µm (Sigma-Aldrich, St. Louis, MO, USA). All
solvents used throughout the project were OPTIMA grade (Fisher Scientific). Semipreparative HPLC was carried out on an Agilent 1200 series equipped with an
autosampler, diode array detector, quaternary pump, and 96-well plate fraction collector
with a Phenomenex Luna® 5 µm C18(2), 100 Å, LC column (250 x 10 mm) as the
stationary phase. All semi-preparative HPLC experiments used a flow rate of 4 mL/min.
Authentic standards of 2,3,4,5-tetrabromopyrrole (Cat. L165042) and 3,4dibromopyrrole-2,5-dione (Cat. 553603) were purchased from Sigma-Aldrich and
dissolved in dimethyl sulfoxide (DMSO) for use in activity assays.
Bacteria Culture and Chemical Library Production. Currently the Mincer
Laboratory maintains over 2000 unique marine microbial isolates for chemical
exploration. All pure cultures are cryopreserved in 10% sterile DMSO and stored at 85ºC. A “starter” culture was prepared by inoculating 100 µL of frozen culture in 6 mL
of TSW media (1 g tryptone in1 L of 75:25 seawater/MilliQ water) and incubated at
23ºC, 100 rpm for 3 d. In general, 1.5 L of TSY media (1 g tryptone, 1 g yeast extract,
75% seawater) is inoculated with 1.5 mL of “starter” culture and grown at 100 rpm for 8
d at 23ºC. Twenty four hours before culture filtration (Day 7), 20 mL of 1:1 mixture of
sterile, washed Amberlite® XAD-7 and XAD-16 resin was added to the cultures. On the
eighth day, the resin was filtered from the bacterial culture under vacuum, desalted by
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rinsing with MilliQ water, and allowed to dry overnight at room temperature. Metabolites
were eluted from the resin first in 100 mL of (1:1) MeOH:DCM, followed by 100 mL of
MeOH. This crude organic extract was then dried under vacuum centrifugation
(ThermoSavant). Dried extracts were subsequently resuspended in DMSO at 100 mg/mL
and stored at -85ºC until further testing in bacterial susceptibility assays.
Bacterial Susceptibility Determinations. Whole-cell assays were used to search for
efflux pump inhibitors for three archetype RND efflux pumps (AcrAB-TolC, MexABOprM, and MexXY-OprM) that are known to contribute to antibiotic resistance in
Enterobacteriaceae and P. aeruginosa clinical isolates. Escherichia coli strains
engineered to overexpress RND transporters were generous gifts from Dr. C. Elkins
(U.S.F.D.A)30 and Dr. Y. Matsumoto (Osaka University).63 Isolates used for screening
include AG102 (derived from AG100; E. coli K-12), an isolate that overexpresses
AcrAB-TolC efflux system due to a mutation in the MarR (marR1) which increases the
expression of MarA, a global regulator, which in turn results in the overexpression of
AcrAB-TolC efflux system;30 and two E. coli MG1655 deletion mutants (ΔacrB ΔtolC)
that have been transformed with the plasmid carrying genes mexAB-oprM (MG1655
ΔBC/pABM) and mexXY-oprM (MG1655 ΔBC/pXYM) from P. aeruginosai.63 E. coli
strains harboring plasmids were always cultured in a medium containing 100 µg/mL
ampicillin and 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG).
Minimum inhibitory concentrations (MICs, defined as the lowest concentration that
will inhibit detectable culture growth) of the antibiotics (chloramphenicol and
erythromycin, both of which are substrates of RND pumps)30, 64-67 were determined using
a twofold standard microdilution method in Muller-Hinton broth (MHB) in microtiter
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plates as defined by the National Committee for Clinical Laboratory Standards68 for each
of the three E. coli strains. Bacterial susceptibility of crude extracts were tested in
duplicate at 1 mg/mL and determined by rapid p-iodonitrotetrazolium chloride (INT)
colorimetric assay in 96-well microtiter plates in a final volume of 200 µL as described in
Kuete et al. 2010.69 The INT assay evaluates if crude extracts have an MDR reversal
effect (so called ‘MIC/4’, defined as reducing by at least fourfold the antibiotic MICs) by
examining the growth of our test E. coli strains in the presence of crude extract and either
chloramphenicol or erythromycin at concentrations at ¼ their MICs. If the crude extract
is capable of potentiating the concentration of antibiotic needed to inhibit the growth of
one or more test strains of MDR E. coli, these initial “hits” were then prioritized for
further testing (in a serial dilution series) in the presence and absence of antibiotic via the
INT assay to establish if EPI-like activity was present. Wells containing MHB, inoculum
and DMSO at a final concentration of 1% served as a negative control. Phenylalanyl
arginyl β-naphthylamide (PAβN, general RND pump inhibitor) was used as a positive
control at 30 µg/mL in INT assays.
Culture Production Scale-up, Bioassay Guided Fractionation, and Chemical
Analysis. Marine isolate A757 (GenBank KM596702), determined to be most closely
related to P. piscicida by 16S rRNA sequence comparison, was targeted for scaled-up
regrowth to obtain additional material for chemical identification of the putative EPI
compound. A starter culture of A757 was used to inoculate eleven, 1.5 L Fernbach flasks
for a total of 16.5 L of culture medium that was processed as described in “Bacteria
Culture and Chemical Library Production”, yielding a total of 1729.7 mg of crude
organic extract. At each subsequent fractionation step an aliquot of material was
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resuspended in DMSO and assayed in the INT assay against MG1655 ΔBC/pXYM to
confirm retention of MDR reversal activity. A total of 1.7 g of crude extract was applied
to a silica gel column and eluted with a step-gradient of 100% isooctane, 4:1
isooctane/EtOAc, 3:2 isooctane/EtOAc, 2:3 isooctane/EtOAc, 1:4 isooctane/EtOAc,
100% EtOAc, 1:1 EtOAc/MeOH, and 100% MeOH, yielding eight fractions. Active
constituents eluted with 3:2 isooctane/EtOAc and 2:3 isooctane/EtOAc, were combined,
and chromatographed on a semipreparative HPLC using a gradient of ACN (0.1% formic
acid) and H2O (0.1% formic acid). Chromatography methods were as follows: hold at 5%
ACN for 5 mins, ramp to 40% ACN over 5 min, hold at 40% ACN for 2 mins, ramp to
95% ACN over 5 min, hold at 95% ACN for 7 min, ramp down to 5% ACN and hold for
4 min. Active constituents eluted with 95:5 ACN/H2O at a flow rate of 4 mL/min over 28
min into a 96 deep-well plate. Two wells on the 96 deep-well plate responsible for the
activity were combined and subject a second round of semipreparative HPLC (ramp from
55-75% ACN over 20 min; ramp to 95% ACN; hold at 95% ACN for 6 min; ramp to
55% ACN and hold for 2 min, 4 mL/min flow rate), with active constituents eluting with
70:30 ACN/H2O into a 96 deep-well plate resulting in activity spread over three wells
containing 14.4 mg of material. LC-MS analysis with acidified solvents (0.1% formic
acid) was performed on the active fraction with a solvent gradient of 6:94 MeOH/H2O
ramping to 8:92 MeOH/H2O over 25 mins, at a flow rate of 0.2 mL/min, which led to the
identification of 3,4-dibromopyrrole-2,5-dione, the major component of the fraction.
NMR spectra of 3,4-dibromopyrrole-2,5-dione from A757 and an authentic standard are
available in Figures S2-5 in Supporting Information.
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Checker board Assay. To assess the interaction between different classes of
antibiotics and 3,4-dibromopyrrole-2,5-dione, we performed standard checkerboard
assays in which the MICs of antibiotics were determined in the presence of different
concentrations of 3,4-dibromopyrrole-2,5-dione. Standard checkerboard titration
microtiter plate assays were performed as described in65, 70 to determine the fractional
inhibitory concentrations (FICs) of 3,4-dibromopyrrole-2,5-dione against various
antibiotics (chloramphenicol, ciprofloxacin, erythromycin, kanamycin, levofloxacin,
oxacillin, piperacillin, and tetracycline) for all three E. coli strains.
Hoechst Accumulation and Efflux Assay. To truly be considered an EPI, the
compound must increase the level of accumulation and decrease the level of extrusion of
efflux pump substrates. The fluorescent DNA-binding dye Hoechst 33342 (H33342) is a
substrate for RND pumps, is easily detected in the cell, can freely permeate the outer
membrane, and can act as a reporter -- all allowing for quantification of transport across
living cells.71 Efflux competent cells extrude H33342 and accumulate dye at a relatively
slow rate, resulting in low levels of background fluorescence. Conversely, effluxdefective cells (e.g., presence of EPI) accumulate intracellular levels of H33342 at a
higher rate, resulting in fluorescence retention. Wild-type E. coli K-12 strain, AG100,
and AG100A, the ΔacrAB mutant, were a generous gift from Dr. M. Viveiros
(Universidad Nova de Lisboa, Portugal) and used in accumulation and efflux assays.72, 73
Experiments were performed in microtiter plate format as described in74, 75 using H33342
as described in71 at a concentration that does not affect the growth of E. coli strains. All
wells were performed in duplicate. Heat-inactivated bacteria were used as a positive
control to assess maximal dye accumulation (data not shown).
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For accumulation assays, in efflux competent cells like AG100, H33342 would be
extruded resulting in low levels of background fluorescence, while the presence of a
putative EPI would cause intracellular H33342 accumulation. Moreover, AG100A,
engineered to lack efflux pumps, was used to confirm that 3,4-dibromopyrrole-2,5-dione
is indeed targeting efflux pumps, and that MDR reversal is limited to efflux pump overexpressing test E. coli strains. Specifically, accumulation of H33342 in AG100A cells
would be unaffected by the presence of 3,4-dibromopyrrole-2,5-dione. Briefly, AG100
and AG100A were grown in Luria Broth (LB) at 37oC and 200rpm until an OD600 of 1.0
then pelleted at 3000 rpm for 15 min, washed twice with phosphate buffered saline
(PBS), and diluted in PBS (without glucose) to OD600 0.3. The following conditions were
used to achieve a minimal accumulation of H33342 in AG100 and AG100A cells: the use
of 2.5 µM H33342 in the presence of 22 mM glucose at 37oC. PAβN (15.6 µg/mL) was
used as a positive control. Fluorescence values for wells containing media and
compounds only were subtracted from those containing bacteria to control for any
background fluorescence due to the presence of test compounds. Bacteria in PBS without
H33342 + glucose + 3,4-dibromopyrrole-2,5-dione were also used as a control (data not
shown). Bacterial cells were allowed to incubate for ~30 min until H33342 accumulation
stabilized, after which 3,4-dibromopyrrole-2,5-dione (concentrations ranging from 0.06 –
64 µg/mL) and PAβN (15.6 µg/mL) were added. Accumulation of H33342 was
continuously monitored (Ex350nm/Em460nm) for another 60 min using a SpectraMax
M2.
For efflux assays, a time-dependent decrease in fluorescence of H33342-loaded AG100
would be observed only when efflux is active, while the presence of a putative EPI would
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cause the retention of H33342 over time. Briefly, AG100 cells were grown, pelleted and
washed as described above, then “loaded” with H33342 (2.5 µM) and either PAβN (15.6
µg/mL) or 3,4-dibromopyrrole-2,5-dione (concentrations ranging from 1 – 64 µg/mL)
under conditions that favor maximal accumulation (no glucose, 25oC). When maximum
accumulation was reached (after 60 min), bacteria were pelleted at 3000 rpm for 3 min,
resuspended in ice-cold PBS, aliquoted into the microtiter plate, and exposed to
corresponding concentrations of either PAβN or 3,4-dibromopyrrole-2,5-dione, with and
without glucose at 37oC. H33342 efflux was continuously monitored by fluorescence at
(Ex 350 nm/Em 460 nm) for an additional 30 min. Values from the “no glucose” control
wells were subtracted from the values obtained from wells containing glucose. To obtain
a comparative analysis of the efflux, the fluorescence data of the H33342-loaded cells
were normalized to 1, thereby establishing a maximum fluorescence value.
Statistical comparisons of H33342 accumulation assay data were performed by
combining fluorescence measurements from the final four time points (period where
accumulation/fluorescence has stabilized) and comparing fluorescence among treatments
using a 1-way ANOVA with a Dunnett’s post-test to determine statistical differences
between treatments and the Hoechst control (Graphpad Prism 6.05). To calculate the
H33342 efflux IC50 concentration of 3,4-dibromopyrrole-2,5-dione, final fluorescence
measurements (from final four data points, as described above), were used to plot efflux
versus EPI concentration. The line was then fitted to a sigmoidal curve and IC50 was
calculated in Graphpad.
Chemical profiling with mass spectrometry. Exuded secondary metabolites produced
by Pseudoalteromonas spp. extracts (n = 36 individual strain extracts) were diluted to 5
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mg/mL in DMSO for untargeted metabolomic fingerprint analysis. Standards of 2,3,4,5tetrabromopyrrole (in a standard curve spanning two orders of magnitude) were used to
determine the retention time and limit of detection (calculated as 3xS.D./slope of
regressed standard curve). Extracts were then profiled (5 µL injections) by reversedphase HPLC/MS ToF, using MeOH (0.1% formic acid) and H2O (0.1% formic acid).
Chromatography methods were as follows: hold at 5% MeOH for 5 min, ramp to 40%
MeOH over 5 min and hold for 2 min, ramp to 95% MeOH over 5 min and hold for 3
min. The first 4.5 min of each run was not injected into the mass spectrometer to avoid
DMSO contamination, and there was an 8 min column equilibrium time between
injections. Column temperature was held at 35°C with a flow rate of 0.2 mL/min.
For profiling, spectra were collected in both positive (+HRESI) and negative (-HRESI)
ionization modes in two separate runs (i.e., no polarity switching). Settings were as
follows for +HRESI: mass correction ions used were 922.0098 m/z and 121.0509 m/z
(injected at source); scanning a 20-3000 m/z range with a scan rate of 1.00; gas
temperature and sheath gas temperature at 350°C. Drying gas flow rate was 8 L/min,
while sheath gas flow rate was 10 L/min with nebulizer pressure set to 40 psi. Capillary
voltage and nozzle voltages were 3500 V and 1000 V, respectively. Fragmentor and
skimmer voltages were 135 V and 65 V, respectively. These settings were held for HRESI except for the mass correction ions used, which were 1033.9881 m/z and
112.9856 m/z in negative mode.
Metabolomics processing and statistical analysis. For metabolomics analysis,
individual spectra were exported from Mass Hunter Workstation as .mzData files and
imported in MZmine76 for preprocessing, as performed in.77, 78 This included mass
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detection, chromatogram building, peak convolution, deisotoping, retention time
normalization, spectral alignment, gap-filling, and duplicate peak filtering. The same
algorithms and settings were used for both +HRESI and -HRESI data, except that
minimal peak thresholds were set to 5000 ion counts for -HRESI and 10,000 ion counts
for +HRESI data. After processing, a list of chemical features (m/z-retention time pairs)
was filtered to only include those features greater than an order of magnitude more
concentrated in a Pseudoalteromonas sample than in the media blank. For +HRESI data,
all features detected between 18.99 – 23.0 min were also removed due to contamination
from polyethylene glycol during those retention times. Filtered datasets were then
imported into Matlab and autoscaled79 before principal component analysis (PCA) using
the PLS Toolbox80, while +HRESI and -HRESI data were analyzed separately. PCA was
used to visualize differences among the exuded metabolite profiles of the
Pseudoalteromonas strains. The loadings for particular principal components were
examined to determine which suites of chemical features were likely to be differentially
expressed35 in different clades of Pseudoalteromonas, and in particular Clade IV. Mass
Hunter Workstation (Qualitative Analysis) was used to confirm the presence of particular
chemical features in raw (unprocessed) mass spectra, and to confirm isotopic
distributions of any halogenated chemical features that were important in distinguishing
Pseudoalteromonas Clade IV in the PCA. To screen for the presence of known
Pseudoalteromonas-specific metabolites in our extracts, a literature search was
performed and previously described compounds (including their names, monoisotopic
mass, and molecular formulae) were compiled into our in-house “Pseudoalteromonas
database.” The feature list generated in MZmine (see above) was then searched against
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this database (assuming a [M-H]- adduct for -HRESI or [M+H]+ adduct for +HRESI) and
with a mass error threshold of ≤ 5.0 ppm.
Phylogenetic Analysis. The evolutionary history was inferred using the NeighborJoining method81 and the optimal tree is shown for topology. The percentage of replicate
trees in which the associated taxa clustered together in the bootstrap test (1000
replicates)82 are shown next to the branches for Neighbor Joining (left) and Maximum
Likelihood (right). The evolutionary history was inferred by using the Maximum
Likelihood method based on the Kimura 2-parameter model.83 Initial tree(s) for the
heuristic search of the Maximum Likelihood tree nodes were obtained automatically by
applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated
using the Maximum Composite Likelihood (MCL) approach. The tree is drawn to scale,
with branch lengths in the same units as those of the evolutionary distances used to infer
the phylogenetic tree. The evolutionary distances were computed using the Jukes-Cantor
method84 and are in the units of the number of base substitutions per site. The analysis
involved 73 nucleotide sequences. All positions containing gaps and missing data were
eliminated. There were a total of 399 phylogenetically informative positions in the final
dataset. Evolutionary analyses were conducted in MEGA6.85
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and database annotation are reported in Supporting Information. This material is available
free of charge via the Internet at http://pubs.acs.org.
Accession Codes.
Accession numbers for Pseudoalteromonas sp. strains identified in our screening
efforts are deposited in GenBank (KM596668 through KM596703), and metadata
describing their coordinates of collection, date, sample description, and strain collection
number can be found in Table S1 in Supporting Information.
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Figure 1. Effect of 3,4-dibromopyrrole-2,5-dione on Hoechst 33342 accumulation and
efflux in wild-type (AG100) and transporter-deficient (AG100A) E. coli. Hoechst 33342
accumulation in AG100 (A) or AG100A (B) and efflux in AG100 (C) in the presence of a
dilution series of 3,4-dibromopyrrole-2,5-dione. PAβN (15.6 µg/mL) was used as a
positive control.
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Figure 2. Phylogenetic and exo-metabolomic comparison of Pseudoalteromonas sp. (A)
Neighbor-Joining dendogram displaying the evolutionary history of the 16S rRNA gene
sequences of the 36 Pseudoalteromonas spp. featured in this study. Topology of the tree
was tested by 1000 bootstrap replicates and scores are displayed for Neighbor-Joining
(top) and Maximum Likelihood (bottom) at each node. Scores under 50% are not shown.
(B) PCA Scores plot of exo-metabolomes (-HRESI) of, 36 different Pseudoalteromonas
strains representing seven clades (I-VII). The first principal component (PC1) describes
20.7% of the variance while the second principal component (PC2) describes 16.2% of
total variance. Dashed line indicates 95% confidence interval. (C) Heat map displaying
relative abundances of brominated metabolites produced exclusively by
Pseudoalteromonas Clade IV (strains A757, A754, A746, and B149). Colored bar rank
peak areas of the major brominated isotope of each metabolite. Column headings display
each ion (m/z) with retention time (RT) for each ion in minutes. Peak areas were
calculated in MZmine. ND = non-detect.
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Figure 3. Heat map displaying relative abundances of inferred compounds produced by
Pseudoalteromonas isolates from (A) –HRESI and (B) +HRESI mode data. Colored bars
indicate peak areas of each ion (m/z) with the corresponding retention time (RT) in
minutes. Preliminary compound identification is as follows: 2-n-heptyl-4-quinolinol (47),
2-n-pentyl-quinolinol (48), 3-formyl-L-tyrosine-L-threonine dipeptide (49), cyclo-(Lphenylalanyl-4R-hydroxyl-L-proline) (50), three isomers of indole-3-carboxaldehyde
(51), isatin (1H-indole-2,3-dione) (52), three isomers of p-hydroxybenzaldehyde (53),
two isomers of p-hydroxybenzoic acid (54), cyclo-(L-pipecolinyl-L-phenylalanine) (55),
pseudomonic acid C (56), 9H-pyrido[3,4-b]indole (57). Asterisks indicate a low
abundance ion (121.03, RT = 14.49 min) in isolate B149 (peak area = 5129) and isolate
A453 (peak area = 3589). The presence of two inferred compounds (●) 2-n-heptyl-4quinolinol (46) and (▲) cyclo-(L-phenylalanyl-4R-hydroxyl-L-proline) (49) were present
in both –HRESI (A) and +HRESI(B) heat maps. Peak areas were calculated in MZmine.
ND = non-detect.
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CHAPTER 3
This manuscript is formatted for publication in Marine Drugs. The formatting
follows the guidelines set forth by the journal.
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Abstract
The emergence of multidrug resistant (MDR) pathogenic bacteria represents a serious
and growing threat to national healthcare systems. Most pressing is an immediate need
for the development of novel antibacterial agents to treat Gram-negative MDR infections,
including the opportunistic, hospital-derived pathogen, Acinetobacter baumannii. Herein
we report a naturally occurring 1,2-benzisoxazole with minimum inhibitory
concentrations as low as 6.25 μg/mL against clinical strains of MDR A. baumannii. This
molecule represents a new chemotype for antibacterial agents against A. baumannii and is
easily accessed in two steps through total synthesis. Structural analogs suggest that the
natural compound may already be optimized for activity against this pathogen. Further
studies to advance the development of this 1,2-benzisoxazole as an antibiotic for
treatment of MDR A. baumannii infections are strongly warranted.
Keywords: multidrug resistant bacteria, Acinetobacter baumannii, benzisoxazole,
antibacterial
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1. Introduction
Acinetobacter baumannii is a non-fermenting, Gram-negative bacterium
commonly implicated in nosocomial infections such as wound infections, sepsis, and
ventilator associated pneumonia.[1] The World Health Organization recognizes antibiotic
resistance as one of the three greatest threats to human health, and recently classified
carbapenem-resistant A. baumannii as one of the most urgent threats, calling for a
renewed investment in antibiotic development.[2] A. baumannii tenacity in hospitals is
enhanced both by its ability to develop antibiotic resistance and capacity to survive on
surfaces, including skin, for several days.[3] A. baumannii can also spread via
aerosolization, promoting this pathogen’s ability to easily colonize new environments.[46] A. baumannii is a member of the ‘ESKAPE’ pathogens [7] and has garnered
significant attention due to its naturally occurring resistance to the most commonly used
antibiotics.[8] Alarmingly, intensive care unit patients contracting A. baumannii
infections have a high mortality rate (>50%), complicated by the fact that new pan-drug
resistant (PR) strains of A. baumannii with resistance to all treatment options have now
emerged.[1,8-10] Carbapenems, typically in combination with other antimicrobial agents
(e.g. colistin) are a commonly utilized treatment option for MDR A. baumannii but it is
estimated that more than half of MDR strains are now carbapenem-resistant.[1,11,12]
Currently, the polypeptide antibiotic colistin is the primary method of treatment for
patients with carbapenem-resistant A. baumannii; however, this therapy has significant
toxicological and dosing concerns.[1,12] With the lack of new antibiotics in the drug
discovery pipeline to treat Gram-negative infections, coupled with accelerated evolution
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of antibiotic resistance, it is imperative that new antibacterial drugs for treating A.
baumannii infections be developed.[13]
Most antibacterial drugs are products of microbial biosynthesis and derivatives
thereof.[14] Herein we report the identification of a 1,2-benzisoxazole antibiotic
produced by a marine bacterium identified as a Bradyrhizobium denitrificans. A series of
synthetically prepared analogs define key structural features for the antibacterial effects
against A. baumannii. This molecule represents a new lead structure for antibacterial drug
development against clinical isolates of A. baumannii that possess MDR phenotypes.
2. Results
Exudate extract from Bradyrhizobium denitrificans (Isolate B158) was initially
screened in the p-iodonitrotetrazolium chloride (INT) assay to assess MDR reversal
potential.[15] Phylogenetic analysis by 16S rRNA gene sequence comparison indicated
that isolate B158 was most closely related to Bradyrhizobium denitrificans. Bioassayguided fractionation of extract generated from B158 microbial culture resulted in the
isolation of 1 and two other known compounds (lumichrome and (1H-indol-3-yl)
oxoacetamide; see 11 and 12 in Supplementary Materials) [16,17] with varying degrees
of bioactivity.
Compound 1 was isolated as an amorphous white powder. An [M-H]- ion of
150.0204 using HRESIMS indicated a molecular formula of C7H5NO3. 1H-NMR
resonances at δH 7.49, 6.75, and 6.67 as well as the molecular formula suggested 1 to be
3,6-dihydroxy-benzisoxazole.[18] Because of limited quantity of the natural product,
3,6-dihydroxy-benzisoxazole was synthesized (Scheme 1) and determined to be identical
to the natural product by NMR (Table 1) and LC/MS analysis (Figure S2).[18]

61
Scheme 1: Synthesis of 3,6-dihydroxy-benzisoxazole (1). a – H2NOH:HCl/KOH in
Dioxane/H2O; b – CDI/Et3N/THF reflux.

Table 1: Comparison of 1H and 13C NMR data of 1, synthetic 3,6-dihydroxy-1,2benzisoxazole, and published 3,6-dihydroxy-1,2-benzisoxazole.[18] Chemical shifts are
referenced to residual MeOH in CD3OD at δH 3.31 and δC 49.0.

position
3
3a
4
5
6
7
7a

Synthetic 3,6dihydroxy-1,2benzisoxazole (1)

Published 1

Isolated 1

δC, type δH, (J in Hz)
167.6, C
108.2, C
123.6, CH 7.50, d (8.6)
6.77, dd
114.5, CH
(8.6, 1.9)
163.2, C
96.2, CH 6.70, d (1.9)
166.9, C

δC, type
167.4, C
108.1, C
123.6, CH

δH, (J in Hz)

114.5, CH

6.75, d (8.6)

163.1, C
96.2, CH
166.8, C

6.67, s

7.49, d (8.6)

Compound 1 was previously reported to possess growth inhibitory effects against
Gram-negative bacteria, but not Gram-positive pathogens.[19] Because this prior testing
was completed more than 30 years ago, we screened 1 for antibacterial activity against
contemporary and MDR Gram-negative bacteria (data not shown) including two betalactamase producing E. coli, a carbapenemase producing Klebsiella pneumoniae, and an
MDR A. baumannii (L1051). Of the strains included, 1 showed promising activity (MIC
of 8-16 μg/mL) only against the A. baumannii isolate, which merited follow up testing.
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A panel of four unique A. baumannii strains was compiled to assess the
effectiveness of 1 in clinically relevant, antibiotic resistant strains. The panel included
one strong biofilm forming strains (L1184), one moderate biofilm forming strain
(L1227), one weak biofilm forming strain (L1222), and one biofilm non-forming strain
(L1051). Two strains (L1222 and L1051) were classified as multi-drug resistant (MDR)
organisms by having non-susceptibility to one or more agents in three or more
antimicrobial categories using previously published guidelines.[20] Minimum inhibitory
concentrations (MICs) were determined for 1 (Table 2) to be in the range of 6.25 μg/mL
to 50 μg/mL with the most potent antibacterial effects against the MDR strains L1222
and L1051 (6.25 and 12.5 μg/mL, respectively). The strong biofilm forming strains
L1227 and L1184 were not as sensitive to 1 with MICs of 25 and 50 μg/mL, respectively.
All minimum bactericidal concentrations (MBCs) for 1 were >100 μg/mL.
To further understand the structural requirements necessary for the antibacterial
effects of 1 against A. baumannii, as well as to potentially improve upon the potency of 1,
we synthesized and purchased analogs to perform a structure activity relationship (SAR)
study (Figure 1). None of the analogs (2-10) demonstrated increased potency against the
panel of A. baumannii strains (Table 2). However, structural requirements for optimal
potency were revealed. Replacement of the hydroxyl substituent at C6 (as in 2-6)
displayed marked decreases in potency. Based on these data, a hydrogen bond donor
substituent at C6 appears to be required for antibacterial effects, with hydroxyl (1) as the
preferred substituent over amino (5). Though the C6 methoxyl group (6) did not
completely abolish activity, the dramatic decrease in potency concludes that alkyl
modifications to the hydroxyl group are unlikely to improve potency in this

63
pharmacophore. Because of the preference of the hydroxyl substituent at the C6 position,
it was also investigated whether an additional hydroxyl group might improve the activity.
Surprisingly, a second hydroxyl group at C4 (7) abolished the antibacterial activity.

Table 2: MIC values for analog compounds 1-10 against A. baumannii strains. Values in
bold indicate an inhibition was shown.

A.
Source
baumannii
Strain
L1051*
Clinical

MIC Values
(μg/mL)
4
5

1

2

3

12.5

>100

>100

>100

6

7

8

9

10

50

>100

>100

>100

>100

>100

L1222*

Blood

6.25

>100

>100

>100

50

100

>100

>100

>100

>100

L1227

Blood

25

>100

>100

>100

50

100

>100

>100

>100

>100

L1184**

Urine

50

>100

>100

>100

50

>100

>100

>100

>100

>100

*Multi-drug resistant organism (MDRO)
**Strong biofilm forming organism

Figure 1: Panel of compounds tested for MICs against A. baumannii in SAR study.
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In addition to substituents on the benzene ring, the necessity of the isoxazole ring
to the pharmacophore was investigated. Methylation of the nitrogen atom (8 and 9) led to
inactive products; it is noted that this modification leads to loss of conjugation in the
hydroxyl-isoxazole ring. Similarly, antibacterial activity was also completely absent for
the oxazolone analog (10).

3. Discussion
Current therapies for MDR A. baumannii are failing. Resistance to the preferred
antibiotic class, carbapenems, is rising and many infections are treated with colistin
which has serious concerns of neurotoxicity and nephrotoxicity.[1] With a dwindling
supply of viable treatments, investigation of new chemical scaffolds with antibacterial
effects against A. baumannii is critical. 1,2-benzisoxazoles, especially the optimized
structure in 1, represent a new chemotype for the development of therapeutics to treat
MDR A. baumannii infections.
From the panel of analogs tested, it appears that the structural features in the
natural product 1 are necessary components of the pharmacophore. A hydrogen bond
donor is necessary at C6, and a hydroxyl is preferred over an amino group. Modifications
to the heteroaromatic ring are detrimental when the isoxazole confirmation is not
retained. Further optimization of the structure for antibacterial effects against A.
baumannii would include determining if the 3-position is modifiable, as well as exploring
other positions on the benzene ring for substitution.
1,2-benzisoxazoles are bicyclic, heteroaromatic structures found in many
approved drugs.[21,22] In general, 1,2-benzisoxazoles are able to cross the blood brain

65
barrier (BBB) and have been classified as privileged structures for drug design for CNS
disorders and other therapeutic areas.[21,22] The heterocyclic ring structure of 1 shares
similarities to two clinically used antibiotics: cycloserine and linezolid (and other
oxazolidinone antibiotics). Interestingly, cycloserine was inactive against our panel of A.
baumannii strains (data not shown). Oxazolidinone antibiotics are only effective against
Gram-positive pathogens, and match the ring structure of the inactive 10, further
supporting the highly specific nature of the 1,2-benzisoxazole pharmacophore.
In the search for antibacterial compounds for MDR pathogens, it has been shown
that ‘old’ antibiotics that have been excluded from the clinic for decades can be useful as
alternative treatment options.[23,24] In addition to older clinical antibiotics, there are
many antibacterial compounds discovered decades ago that have not been developed,
including compound 1 that may be useful against modern MDR pathogens. Compound 1
was previously reported to possess potent growth inhibition of Gram-negative bacteria
including E. coli, Proteus spp., Salmonella spp., Klebsiella pneumoniae, Enterobacter
spp., and Serratia marcescens, as well as low toxicity with an LD50 of over 1500 mg/kg
in mice.[18,19] No inhibition was observed with the Gram-positive bacteria
Staphylococcus aureus, Bacillus spp., Micrococcus sp., Corynebacterium sp., or the
Gram-negative Pseudomonas spp.[18,19]
Narrow spectrum of antibacterial drugs are becoming more desirable due to
advances in diagnostic tests and changes to the regulatory environment.[25] Resistance is
expected to develop more slowly to narrow spectrum antibiotics and collateral damage to
the gut microbiome, such as with antibiotic-associated colitis, is less likely.[26] We
suggest that further studies advancing the development of 1,2-benzisoxazoles, including
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1, as anti- A. baumannii antibiotics are warranted. Investigations into its cellular target, in
vivo efficacy, and further structure activity relationships are vital next steps to improving
the outlook for treatment of infections with MDR A. baumannii.

4. Materials and Methods
4.1 General Experimental Procedures
NMR experiments were conducted using an Agilent NMRS 500 MHz spectrometer
with (CD3)2SO (referenced to residual DMSO at δH 2.50 and δC 39.5) or CD3OD
(referenced to residual MeOH at δH 3.31 and δC 49.0) at 25 °C. High Resolution
Electrospray ionization mass spectra (HRESIMS) were acquired using either an AB
Sciex TripleTOF 4600 spectrometer in the negative ion mode or Agilent Technologies
6230 ToF with a Dual Jet Stream Electrospray Ionization source, equipped with an
Agilent 1260 Infinity series HPLC. Flash chromatography was completed with a
Combiflash Rf200 equipped with a 40 g silica gel RediSepRf High Performance Gold
column (Teledyne ISCO). HPLC experiments were performed on a Shimadzu
Prominence-i LC-2030C system equipped with a diode array detector or an Agilent 1200
series equipped with an autosampler, diode array detector, quaternary pump and 96 well
plate fraction collector. Semi-preparative HPLC purifications were accomplished with a
Waters XBridge Prep C18 5 µm, 10 × 250 mm column at 4.5 mL/min. The exact
equipment in separation and identification used is specified below. All chemicals and
solvents were at least reagent grade and purchased commercially (Sigma Aldrich, St.
Louis, MO).
4.2 Bacterial Strains
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We examined four clinically diverse strains of A. baumannii obtained from
patients at Rhode Island Hospital, American Type Culture Collection (ATCC), and the
Biodefense and Emerging Infection Research Resources Repository (BEI). Strains
depicted various biofilm-forming capabilities (described in Supplementary Materials [2731]) (non adherent [n=1]; weak [n=1]; moderate [n=1]; strong [n=1]) and resistance
patterns, with two multi-drug resistant organisms (MDROs) and two non-MDROs.
MDRO was defined as organism with non-susceptibility to one agent in three
antimicrobial classes, according to previously described definitions.[20] These strains are
available in the investigators’ laboratory and stored frozen at -80 ºC in 20% glycerol.
4.3 A. baumannii Susceptibility Testing
Minimum inhibitory concentrations (MICs) of pure compounds against clinical
isolates of A. baumannii were determined in duplicate by broth microdilution in
accordance with Clinical Laboratory Standards Institute (CLSI) standards.[32,33] Due to
antibacterial activity of DMSO at high concentrations,[34] our methods were modified to
ensure DMSO concentrations do not exceed 2.5%. Plates were subsequently incubated at
37 C for 24 h. After 24 h, minimum bactericidal concentrations (MBCs) were
determined in duplicate for each antimicrobial compound in accordance with
CLSI.[32,33]
4.4 Cultivation and Extraction of Marine Bacterial Strain B158
Marine isolate B158 was originally isolated from the oral cavity of the
ctenophore, Mnemiopsis leidyi from Eel Pond, Woods Hole, MA, U.S.A. in September
2012. The isolate was streaked to purity on TSW (1 g of tryptone in 1 L of 75:25 natural
seawater/Milli-Q water) agar plates and cryopreserved in 10% sterile DMSO and stored
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at -85 °C. Strain B158 was identified as B. denitrificans based on 98% nucleotide
sequence identity to available B. denitrificans 16S rDNA sequence (Genbank Accession
Number MF113387). A “starter” culture was prepared by inoculating 100 µL of
cryopreserved culture in 6 mL of TSW media and incubated at 23 °C, 100 rpm for 3 days.
A 1.5 L fernbach flask containing TSY media (1 g of tryptone, 1 g of yeast extract in 1 L
of 75:25 natural seawater/Milli-Q water) was inoculated with 1.5 mL of “starter” culture
and grown at 100 rpm for 8 d at 23 °C. Twenty-four hours before culture filtration (day
7), 20 mL of a 1:1 mixture of sterile, washed Amberlite XAD-7 and XAD-16 resin was
added to the cultures. On the eight day of growth, the resin was filtered from the bacterial
culture under vacuum, desalted by rinsing with Milli-Q water, and allowed to dry
overnight at room temperature. Secreted metabolites were eluted from the resin by two
extractions in 100 mL of (1:1) MeOH/CH2Cl2, followed by 100 mL of MeOH. Both
extractions were combined and dried under vacuum centrifugation (ThermoSavant). The
dried extract was resuspended in DMSO at 100 mg/mL and stored at -85 °C until further
testing in bacterial susceptibility assays against E. coli strains overexpressing RND
transporters.[15]
Once isolate B158 was determined to contain active compound(s), a total of 118.5
L of B158 culture was grown in 1.5 L Fernbach flasks to obtain enough crude material
for structural elucidation. Briefly, 2 mL of “starter” culture in TSW was used to inoculate
Fernbach flasks containing 1.5 L of 1 x TSY and allowed to grow for 7 days at 100 rpm
at 23 °C. On day 7, 20 mL (approximately weight = 7.8 g) of 1:1 mixture of sterile
Amberlite XAD-7 and XAD-16 resin that had been extensively washed in organic
solvent, dried, and autoclaved was added to each 1.5 L culture. After 24 h, the resin was
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filtered from the bacterial culture through combusted stainless steel mesh under gentle
vacuum (<5 in Hg), desalted by rinsing with MilliQ water, pooled, and dried overnight at
room temperature. Each 1.5 L resin equivalent was extracted with 100 mL of (1:1)
MeOH/CH2Cl2, followed by MeOH. This crude extract was dried under vacuum
centrifugation and stored at -85 °C until bioassay guided fractionation.
4.5 Bioassay Guided Fractionation of Exudates from B158
Assessment of crude extracts via MDR reversal assays with E. coli MDR strains
MG1655 ΔBC/pABM, and MG1655 ΔBC/pXYM separately overexpressing two
Resistance Nodulation cell Division (RND) transporters indicated the presence of active
compound(s) and was completed following previously published methods.[15] Crude
extract was applied to a silica gel column (40-60 µm, 60Å) and eluted with a stepgradient of isooctane, (4:1) isooctane/ EtOAc, (3:2) isooctane/EtOAc, (2:3)
isooctane/EtOAc, (1:4) isooctane/EtOAc, EtOAc, (1:1) EtOAc/MeOH, and 100% MeOH,
yielding eight fractions. Bacterial susceptibility testing in the INT assay indicated activity
to be localized to the following three gradients: (1:4) isooctane/EtOAc, EtOAc, (1:1)
EtOAc/MeOH. Material from these three fractions were combined and the material was
further separated by solid-phase extraction (Supelclean ENVI-18) eluting with a stepgradient of (20:1) water/MeCN, (4:1) water/MeCN, (3:2) water/MeCN, (2:3)
water/MeCN, (1:20) water/MeCN, and acetone. All solvents, except acetone, were
acidified with 0.1% formic acid (FA). The active fraction eluted with (4:1) and (3:2)
water/MeCN gradients. The active fraction totaling (700 mg) was separated further into
96-deep well plates by semipreparative HPLC using an Agilent 1200 series HPLC and a
Phenomenex Luna® 5 µm C18 (2) 100 Å, LC column (250 x 10 mm) as the stationary
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phase, heated to 30 °C and a gradient of water and MeCN with a flow rate of 4 mL/min.
All solvents were acidified with 0.1% FA. Contents of the 96-deep well plate were
concentrated in vacuo and tested in the INT assay. Two fractions were found to contain
the desired activity, wells G6 to H6 (most active) totaling 32.4 mg and H8, A9, B9
(minor activity) totaling 25.1 mg, which eluted (3:2) water/MeCN and (1:1)
water/MeCN, respectively. The fraction containing wells G6 to H6 was further separated
by analytical HPLC using an Agilent 1260 series LC-MS and a Phenomenex Kinetex 2.6
µm C18 100Å, LC column (150 x 2.1 mm) as the stationary phase, heated to 30 °C and a
gradient of water and MeOH with a flow rate of 0.2 mL/min. All solvents were acidified
with 0.1% FA. Compound 1 eluted at 13.2 min corresponding to (7:3) water/MeOH and
yielded a total of 1 mg of white powder.
4.6 Compound Data
3,6-dihydroxy-1,2-benzisoxazole (1): Synthesis of 3,6-dihydroxy-1,2-benzisoxazole was
performed as previously reported.[35] Hydroxylamine hydrochloride (2.50 g, 36.0 mmol)
was added to a stirring solution of KOH (2.69 g, 47.9 mmol) in water (30 mL) at room
temperature. Methyl 2,4-dihydroxy-benzoate (1.01 g, 6.0 mmol) dissolved in 1,4 dioxane
(5 mL) was added dropwise to the hydroxylamine solution and stirred for 24 h at room
temperature. After removing the 1,4 dioxane in vacuo, the pH was adjusted to 1 using 3N
HCl and extracted with EtOAc (3 x 50 mL). The organic layers were combined and dried
over Na2SO4, filtered and concentrated in vacuo. The resulting residue was purified by
silica gel flash chromatography using a gradient of 20-100% EtOAc/hexanes to afford
2,4-dihydroxy-benzohydroxamic acid (765.7 mg, 76% yield).
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2,4-dihydroxy-benzohydroxamic acid (161.4 mg, 0.96 mmol) was dissolved in
anhydrous tetrahydrofuran (10 mL) under N2. Dry 1,1′-carbonyldiimidazole (CDI) (489.2
mg, 3.0 mmol) was added to the mixture and heated at reflux conditions for 30 min. Et3N
(210 μL, 1.5 mmol) was then added and the reaction proceeded at reflux for 18 h. The
THF was removed in vacuo and the resulting residue was reconstituted in 1N HCl and
extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over
Na2SO4, filtered and concentrated. The resulting residue was purified by silica gel flash
chromatography using a gradient of 30-50% EtOAc with 0.1% FA/hexanes to afford 3,6dihydroxy-1,2-benzisoxazole (107.7 mg, 74% yield, overall yield 56%). Prior to
bioassay, this product was further purified by HPLC with an isocratic method of 20%
MeOH in H2O with 0.1% FA to afford pure 1 (white powder). 1H-NMR (500 MHz,
CD3OD),

13

C-NMR (125 MHz, CD3OD) see Table 1. HRMS calcd for C7H4NO3:

150.0191. Found [M-H] 150.0206.
3-hydroxy-1,2-benzisoxazole (2): Compound 2 was prepared from commercially
available methyl salicylate (methyl 2-hydroxy-benzoate) according to the scheme used to
prepare 1. 2 was further purified by semi-preparative HPLC using an isocratic method of
50% MeOH in H2O with 0.1% FA to afford pure 2 (white powder). 1H-NMR (500 MHz,
(CD3)2SO) δ 7.31 (1H, t, J = 7.0), 7.54 (1H, d, J = 8.2), 7.59 (1H, t, J = 7.9), 7.75 (1H, d,
J = 8.0), 12.45 (1H, br s). 13C-NMR (125 MHz, (CD3)2SO) δ 110.0, 114.6, 121.4, 122.9,
130.5, 163.0, 165.4. HRMS calcd for C7H4NO2: 134.0242. Found [M-H] 134.0251.
3-hydroxy-6-fluoro-1,2-benzisoxazole

(3):

Compound

3

was

prepared

from

commercially available methyl 2-hydroxy-4-fluoro-benzoate according to the scheme
used to prepare 1. 3 was further purified by semi-preparative HPLC using the method: 12
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min gradient from 55-100% MeOH in H2O with 0.1% FA to yield pure 3 (white powder).
1

H-NMR (500 MHz, CD3OD) δ 7.09 (1H, td, J = 1.5, 9.1), 7.22 (1H, dd, J = 1.5, 9.1),

7.70 (1H, dd, J = 5.2, 8.9).

13

C-NMR (125 MHz, CD3OD) δ 98.3 (d, J = 27.7), 112.8,

113.0 (d, J = 25.7), 123.9 (d, J = 11.5), 165.7 (d, J = 14.4), 166.3 (d, J = 249.0), 167.0.
HRMS calcd for C7H3FNO2: 152.0148. Found [M-H]: 152.0271.
3-hydroxy-6-(benzyloxy)-1,2-benzisoxazole (4): Commercially available methyl 2,4dihydroxy-benzoate (1.0 g, 5.92 mmol) was dissolved in 10 mL acetone and treated with
K2CO3 (1.0 g, 7.24 mmol) and NaI (0.25 g, 1.67 mmol). The resulting suspension was
stirred for 10 min under N2 and then benzyl bromide (700 μL, 5.85 mmol) was added
dropwise. The reaction mixture was stirred for 24 h at ambient temperature. After
removing the acetone in vacuo, the resulting residue was resuspended in H2O and
extracted with EtOAc (4 x 40 mL). The organic layers were combined, dried over
Na2SO4, and concentrated in vacuo. The residue (1.8 g) was purified by silica gel flash
chromatography using a gradient of 10-100% EtOAc in hexanes to afford methyl 2hydroxy-4-benzyloxy-benzoate (687.4 mg, 45.5% yield) as white crystals. Methyl 2hydroxy-4-benzyloxy-benzoate was then further elaborated per Scheme 1 to afford
analog 4, which was further purified by semi-preparative HPLC using an isocratic
method of 50% MeOH in H2O with 0.1% FA (white powder). 1H-NMR (500 MHz,
(CD3)2SO) δ 5.17 (2H, s), 6.94 (1H, d, J = 8.7), 7.15 (1H, s), 7.34 (1H, t, J = 7.4), 7.40
(2H, t, J = 7.4), 7.46 (2H, d, J = 7.4), 7.60 (1H, d, J = 8.6).

13

C-NMR (125 MHz,

(CD3)2SO) δ 69.9, 94.5, 108.3, 113.4, 122.0, 127.9 (2C), 128.1, 128.5 (2C), 136.5, 161.1,
164.9, 165.7. HRMS calcd for C14H10NO3: 240.0661. Found [M-H] 240.0564.
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3-hydroxy-6-amino-1,2-benzisoxazole

(5):

Compound

5

was

prepared

from

commercially available methyl 2-hydroxy-4-amino-benzoate (AK Scientific, Union City,
CA) according to the scheme used to prepare 1 with minor modification. The ring closing
step was accomplished with CDI/MeCN instead of CDI/THF/Et3N. The resulting mixture
was purified using semi-preparative HPLC with a gradient method from 10-55% MeOH
in H2O with 0.1% FA (white powder). 1H-NMR (500 MHz, (CD3)2SO) δ 5.80 (2H, s),
6.39 (1H, d, J = 1.4), 6.50, (1H, dd, J = 1.5, 8.4), 7.30 (1H, d, J = 8.4). 13C-NMR (125
MHz, (CD3)2SO) δ 91.2, 103.6, 111.8, 121.8, 152.3, 165.6, 165.9. HRMS calcd for
C7H5N2O2: 149.0351. Found [M-H] 149.0323.
3-hydroxy-6-methoxy-1,2-benzisoxazole (6): Compound 6 was purchased commercially
(Sigma Aldrich, St. Louis, MO).
3,4,6-trihydroxy-1,2-benzisoxazole (7): Compound 7 was prepared from commercially
available methyl 2,4,6-trihydroxy-benzoate (abcr GmbH, Karlsruhe, Germany) according
to the scheme used to prepare 1. 7 was further purified from a mixture by semipreparative HPLC with a gradient method of 25-100% MeOH in H2O with 0.1% FA
(white powder). 1H-NMR (500 MHz, (CD3)2SO) δ 6.08 (1H, d, J = 1.3), 6.14 (1H, d, J =
1.3), 10.22 (3H, br s). 13C-NMR (125 MHz, (CD3)2SO) δ 86.8, 96.6, 97.3, 153.8, 161.9,
165.2, 166.6. HRMS calcd for C7H4NO4: 166.0140. Found [M-H] 166.0151.
N-methyl-6-hydroxy-1,2-benzisoxazol-3(2H)-one (8) and N-methyl-6-methoxy-1,2benzisoxazol-3(2H)-one (9): Compounds 8 and 9 were prepared from 1 in a one-step
synthesis and purification. 1 (46 mg, 0.33 mmol) was dissolved in dry MeCN (4 mL) and
K2CO3 (91 mg, 0.66 mmol) was suspended in the solution. Suspension was stirred rapidly
under N2 and excess CH3I (260 μL, 4.2 mmol) was added dropwise and stirred for 18 h at
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room temperature. The reaction was quenched by removing MeCN in vacuo and the
resulting residue was dissolved in 1N HCl. This solution was extracted with EtOAc (3 x
30 mL) and the combined organic layers were dried over Na2SO4, filtered and
concentrated in vacuo. The resulting products were purified by semi-preparative HPLC
using a 12 min gradient from 35-80% MeOH in H2O with 0.1% FA to afford 8 (12.1 mg,
white powder) and 9 (8.5 mg, white powder).
Compound 8: 1H-NMR (500 MHz, (CD3)2SO) δ 3.46 (3H, s), 6.68 (1H, d, J =
1.6), 6.57 (1H, dd, J = 1.6, 8.4), 7.55 (1H, d, J = 8.4), 10.73 (1H, br s). 13C-NMR (125
MHz, (CD3)2SO) δ 33.3, 95.3, 106.8, 113.4, 124.7, 162.3, 163.4, 164.2. HRMS calcd for
C8H8NO3: 166.0504. Found [M+H]: 166.0216.
Compound 9: 1H-NMR (500 MHz, (CD3)2SO) δ 3.51 (3H, s), 3.86 (3H, s), 6.89
(1H, dd, J = 2.1, 8.6), 7.05 (1H, d, J = 2.0), 7.64 (1H, d, J = 8.6). 13C-NMR (125 MHz,
(CD3)2SO) δ 33.2, 56.1, 93.8, 108.1, 113.2, 124.5, 162.2, 163.7, 164.5. HRMS calcd for
C9H10NO3: 180.0661. Found [M+H]: 180.0341.
6-hydroxy-2-benzoxazolinone (10): Compound 10 was purchased commercially (abcr
GmbH, Karlsruhe, Germany).

Supplementary Materials: The following are available online at…. Purification and
dereplication details of compounds 11 and 12 and pertinent NMR and MS data are
included.
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Abstract
In the present study it is shown that although E. coli CFT073, a human uropathogenic
(UPEC) strain, grows in liquid glucose M9 minimal medium, it fails to grow on glucose
M9 minimal medium agar plates seeded with ≤ 106 CFU. The cells on glucose plates
appear to be in a “quiescent” state that can be prevented by various combinations of
lysine, methionine, and tyrosine. Moreover the quiescent state is characteristic of ~ 80%
of E. coli phylogenetic group B2 multilocus sequence type 73 strains as well as 22.5% of
randomly selected UPEC strains isolated from community acquired urinary tract
infections in Denmark. In addition, E. coli CFT073 quiescence is not limited to glucose,
but occurs on agar plates containing a number of other sugars and acetate as sole carbon
sources. It is also shown that a number of E. coli CFT073 mini-Tn5 metabolic mutants
(gnd, gdhA, pykF, sdhA, and zwf) are non-quiescent on glucose M9 minimal agar plates
and that quiescence requires a complete oxidative TCA cycle. In addition, evidence is
presented that although E. coli CFT073 quiescence and persistence in the presence of
ampicillin are alike in that both require a complete oxidative TCA cycle and that each can
be prevented by amino acids, E. coli CFT073 quiescence occurs in the presence or
absence of a functional rpoS gene, whereas maximal persistence requires a nonfunctional rpoS. Our results suggest that interventions targeting specific central
metabolic pathways may mitigate UPEC infections by interfering with quiescence and
persistence.
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Importance
Recurrent urinary tract infections (UTIs) affect 10 to 40% of women. In up to 77% of
those cases the recurrent infections are caused by the same uropathogenic E. coli (UPEC)
strain that caused the initial infection. Upon infection of urothelial transitional cells in
the bladder, UPEC appear to enter a non-growing quiescent intracellular state that is
thought to serve as a reservoir responsible for recurrent UTIs. Here we report that many
UPEC strains enter a quiescent state when ≤ 106 CFU are seeded on glucose M9 minimal
medium agar plates and show that mutations in several genes involved in central carbon
metabolism prevent quiescence as well as persistence, possibly identifying metabolic
pathways involved in UPEC quiescence and persistence in vivo.
Introduction
Uncomplicated urinary tract infections (UTIs) affect about 25% of women in their
lifetime and at least 80% of those infections are caused by uropathogenic E. coli (UPEC)
(1). Recurrent UTIs affect between 10% and 40% of women (2) and in up to 77% of
those cases the recurrent infections are caused by the same UPEC strain that caused the
initial infection (3, 4). UPEC infections generate annual costs in excess of two billion
dollars in the United States alone, placing a significant burden on the health care system
(5). Although the causes of recurrent UTI are complex (6), it appears that UPEC can bind
to, enter, and replicate within superficial facet cells in the human and mouse bladder
epithelium, resulting in biofilm-like intracellular communities (IBCs) (6, 7). IBCs escape
from infected superficial facet cells within hours of development (6). The superficial
facet cells then exfoliate, exposing underlying transitional epithelial cells, which can be
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infected with IBC-derived UPEC progeny (6, 8). Upon infection of urothelial transitional
cells, UPEC appear to enter a non-growing quiescent intracellular state (6, 8). These
quiescent UPEC cells have been called QIRs (Quiescent Intracellular Reservoirs) (6) and
it is thought that QIRs are a major cause of recurrent UTIs (6, 8). QIRs also help to
explain why antibiotics have failed to eradicate UPEC reservoirs in the bladders of mice,
since quiescent UPEC may not be readily affected by antibiotics (6, 8).
The quiescence of QIRs and their insensitivity to antibiotics is reminiscent of the
persister state (8, 9, 10, 11). Persister cells are dormant cells formed in normal microbial
populations as small subpopulations that are highly tolerant to antibiotics, but upon
regrowth in the absence of antibiotics regain full sensitivity (11). Persisters appear to
play a major role in the ability of chronic infections to withstand antibiotic treatment
(11). In the present study, we report that when ≤ 106 CFU of E. coli CFT073, the
prototypic UPEC strain, as well as ~ 80% of phylogenetic group B2 multilocus sequence
type 73 (ST73) strains, of which E. coli CFT073 is a member, are plated on M9 minimal
agar plates containing glucose as sole carbon and energy source, they appear to enter a
“quiescent” state and that mutations in specific metabolic genes appear to prevent that
state. In addition, we show that E. coli CFT073 quiescence also occurs in the presence of
a number of other sugars and acetate as sole carbon sources and that a complete TCA
cycle is required for both generation of E. coli CFT073 quiescent cells on glucose plates
and for formation of persister cells generated in liquid glucose minimal medium in the
presence of ampicillin.
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Materials and Methods
Bacterial strains. The E. coli CFT073, MG1655, and Nissle 1917 strains used in this
study are listed in Table 1. The original E. coli K-12 strain was obtained from a stool
sample from a convalescing diphtheria patient in Palo Alto, CA, in 1922 (12). The
sequenced E. coli MG1655 strain (CGSC 7740) was derived from the original K-12
strain, having only been cured of the temperate bacteriophage lambda and the F plasmid
by means of UV light and acridine orange treatment (12). E. coli Nissle 1917 was
originally isolated during World War I from a soldier who escaped a severe outbreak of
diarrhea (13). It has a beneficial effect on several types of intestinal disorders, is well
tolerated by humans, and has been marketed as a probiotic remedy against intestinal
disorders in several European countries since the 1920s (13). E. coli strains tested for
quiescence in the Testing additional E. coli strains for quiescence on glucose plates and
the Testing additional ST73 strains for quiescence on glucose plates sections in Results
are from the E. V. Sokurenko collection and the E. coli strains used in the Testing 40
UPEC strains isolated from community acquired UTIs in Denmark for quiescence on
glucose plates section in Results are from the N. Frimodt-Møller/ K.L. Nielsen
collection.
Media. LB broth (Lennox) (Difco Laboratories) and LB agar (Lennox) (Difco
Laboratories) were used for routine cultivation. SOC medium was prepared as described
by Datsenko and Wanner (14). Liquid M9 minimal medium (15) and M9 minimal
medium agar plates were supplemented with reagent grade (Sigma-Aldrich, Inc.) Larabinose (0.2%, w/v), N-acetyl-D-glucosamine (0.2%, w/v), L-fucose (0.2%, w/v), Dfructose (0.2%, w/v), D-glucose (0.2%, w/v), D-galactose (0.2%, w/v), D-gluconate
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(0.2%, w/v), glycerol (0.2%, v/v), D-mannose (0.2%, w/v), maltose (0.2%, w/v), Dribose (0.2%, w/v), D-xylose (0.2%, w/v), potassium acetate (0.4%, w/v), sodium
succinate (0.4%, w/v), and various amino acids, as indicated. Since Difco Bacto agar
contains impurities, M9 minimal medium agar plates were made with 1.6% Difco Agar
Noble (Difco).
Lawn assay for quiescence. All E. coli strains were streaked from -80oC stored LB
broth grown cultures diluted 1:1 with 50% (v/v) glycerol to LB agar plates which were
incubated overnight at 37°C. A loopful of cells from each streak plate was then grown
overnight in 10 ml of 0.4% glucose M9 minimal medium at 37°C with shaking in 125 ml
tissue culture bottles. Routinely, 105 CFU from an overnight culture was added to a tube
containing 3 ml of liquid overlay medium (0.2% glucose M9 minimal medium, 0.7%
Difco Agar Noble at 45°C). Each tube containing inoculated overlay medium was
immediately poured on a pre-warmed (37°C) 0.2% glucose M9 minimal medium agar
plate. Inoculated overlays were allowed to solidify (with lids slightly ajar) for 1 h at
room temperature. In addition, as indicated, solidified inoculated overlays were stabbed
with colonies of E. coli MG1655 grown on 0.4% glucose M9 minimal medium agar
plates using sterile toothpicks or were spotted with 5 µl to 20 µl of filtered E. coli
MG1655 culture supernatant, human urine, or defined amino acid solutions. Spots were
allowed to dry prior to incubation of plates. Plates were incubated for 24 h or 48 h at
37°C, as indicated. Strains that grew as lawns on 0.2% glucose M9 minimal medium
agar plates were considered to be non-quiescent and strains that grew in liquid 0.2%
glucose M9 minimal medium, failed to grow on 0.2% glucose M9 minimal medium agar
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plates, but were stimulated to grow around E. coli MG1655 stabs were considered to be
quiescent (see Results).
Insertional mutagenesis. Mini-Tn5 Km (kanamycin) mutants were constructed by
insertional mutagenesis as described previously (16). Briefly, the donor E. coli ATM161
(17) carrying the suicide vector pUT, which contains the mini-Tn5 Km transposon, was
conjugated with the recipient E. coli CFT073 StrR (Table 1) in the following manner. The
donor and recipient strains were grown overnight, with shaking, in LB broth at 30°C.
Aliquots of 100 µl of each culture were mixed together in 5 ml of 10 mM MgSO4 and
filtered through a 0.45 μm pore size membrane filter (EMD Millipore). The filter was
placed on the surface of an LB agar plate and incubated for 5 h at 37°C. Following
incubation, the bacteria on the filter were suspended in 5 ml of 10 mM MgSO4, and 100
µl aliquots of the suspension were plated on LB agar containing streptomycin sulfate
(100 µg/ml) and kanamycin sulfate (80 µg/ml) and plates were incubated for 18 h at
37°C. Individual mini-Tn5 Km mutant colonies were toothpicked to 2 LB agar plates,
one lacking and one containing ampicillin sodium salt (100 µg/ml, Sigma-Aldrich, Inc.).
Colonies that were ampicillin sensitive, signifying loss of the pUT suicide plasmid, were
toothpicked to sterile 16 mm diameter culture tubes containing 250 µl of 0.2% glucose
M9 minimal medium. Culture tubes were incubated overnight at 37°C with shaking, 5
ml of M9 minimal medium lacking a carbon source was then added to each tube, and 3 µl
from each tube was spotted on a 0.2% glucose M9 minimal medium agar plate. Spots
were allowed to dry (with lids slightly ajar) and plates were incubated overnight at 37°C.
Each spotted mini-Tn5 Km mutant that grew was retested by seeding 105 CFU of an
overnight 10 ml liquid 0.4% glucose M9 minimal medium culture on a 0.2% glucose M9
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minimal medium agar plate and incubating at 37°C for 24 hours. The gene inactivated in
each of the mini-Tn5 Km mutants that grew as a lawn was determined by arbitrary PCR
(18), as described below. In addition, to be sure that the mini-Tn5 Km insertion was the
cause of the ability of the individual mutants to grow on glucose plates, the insertion in
each mutant was transferred into a fresh E. coli CFT073 StrR background by the method
of Wanner and Datsenko (14). Each mutant thus obtained was confirmed for the ability
to grow as a lawn on glucose plates and for the position of the insertion within the E. coli
CFT073 chromosome by both PCR and sequencing (see Table 2 for primers). Five
confirmed mutants were isolated from approximately 2000 mini-Tn5 Km mutants tested.
Arbitrary PCR. Arbitrary PCR was performed as described previously (18). Genomic
DNA was isolated from E. coli CFT073 mini-Tn5 Km mutants using the Wizard®
Genomic DNA Purification Kit (Promega). The first round of PCR was performed in 25
µl reactions (1X Standard Taq Reaction Buffer (New England Biolabs, Inc.), 2 mM
dNTPs, 100 µM arbitrary primer 1 (5′GGCCACGCGTCGACTAGTACNNNNNNNNNNNNGATAT-3′), 10 µM Tn5-specific
primer (5′-TCTGGATTTCGATCACGGCAC G T-3′), Taq DNA Polymerase (2 units,
New England Biolabs, Inc.) and DNA from 1.25 µl of an overnight LB broth culture. The
first round cycling conditions were: (i) 4 min at 95°C; (ii) 6 x (30s at 95°C, 30s at 30oC,
1.5 min at 72°C 1.5); (iii) 30 x (30s at 95°C, 30s at 45°C, 2 min at 72°C); (iv) 4 min at
72°C. The second round of PCR used standard conditions and cycling as follows: (i) 4
min at 95°C; 35 x (30s at 95°C, 30s at 55°C, 2 min at 72°C), (iii) 4 min at 72°C with 0.5
µl of the first round PCR product as template and 10 µM arbitrary primer 2 (5′GGCCACGCGTCG ACTAGTAC-3′) and 10 µM of a second Tn5-specific primer (5′-
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TTACCGAGAGCTTGGTAC CCAGTC-3′). The second round of PCR reactions were
column purified with a QIAquick PCR Purification Kit (Qiagen) and sequenced using a
third Tn5-specific primer (5′-GTACCCAGTCTGTGTGAGCAGG-3′). DNA sequencing
was done at the URI Genomics and Sequencing Center, University of Rhode Island,
Kingston, RI using an Applied Biosystems 3130xl genetic analyzer (Applied Biosystems,
Foster City, CA). A BigDye Terminator cycle sequencing kit (version 3.1; Applied
Biosystems) was used for the sequencing reactions. Sequences were compared with the
GenBank DNA sequence database using the BLASTX program.
Identification and quantitation of amino acids in E. coli MG1655 and E. coli
CFT073 50-fold concentrated culture supernatants. E. coli MG1655 was grown
overnight in five 10 ml cultures in liquid 0.4% glucose M9 minimal medium with
shaking at 37°C in 125 ml tissue culture bottles. The cultures were pooled and cells were
centrifuged for 10 min at 8000 x g and resuspended in 1 ml of 0.2% glucose M9 minimal
medium. The 50-fold concentrated cultures were incubated standing overnight at 37°C in
1.5 ml centrifuge tubes (CELLTREAT Scientific Products). Cells were then centrifuged
at 16,000 x g for 3 min and the supernatant was removed and filtered free of bacteria
using a 0.22 µm MCE syringe filter (Fisherbrand). E. coli CFT073 concentrated culture
supernatants were prepared identically.
Amino acids in 50-fold concentrated culture supernatants were identified and
quantified using a slightly modified version of a method described by Yuan et al. (19).
The method uses the AccQ Tag Amino Acid analysis method (Waters Corp., Milford,
MA, USA) with a pre-column derivatization kit
(http://www.waters.com/webassets/cms/support/docs/wat0052881.pdf). Acid hydrolysis
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was not included in the derivatization step to assure that only free amino acids were
quantified. The method uses HPLC to separate the derivatized amino acids and a
fluorescence detector to identify and quantify them. The chromatographic method using
AccQ Tag Eluent A (solvent A) and 60% acetonitrile in water (solvent B) is as follows:
consecutive linear gradients of 0-2% B over 0.5 min; 2-7% B over 14.5 min; 7-10% B
over 4 min; 10-20% B over 11 min; 20-36% B over 10 min; and 36-100% B over 5 min.
The method totals 45 min of gradients and an additional 11 min washout phase. The flow
rate was constant at 0.7 ml/min using a Waters AccQ Tag column (150 x 3.9 mm) held at
a 40°C and injecting 5 µl aliquots. The fluorescence detector was set to an excitation
wavelength of 250 ηm and emission wavelength of 395 ηm per manufacturer’s
instructions. Amino acids were identified by comparison to derivatized amino acid
reference standards in the following order: tryptophan, 6-aminoquinoline (AMQ, a
product of the derivatization process), aspartic acid, serine, glutamic acid, glycine,
histidine, ammonium ion, arginine, threonine, alanine, proline, cysteine, tyrosine, valine,
methionine, lysine, isoleucine, leucine, phenylalanine. A calibration curve was generated
to quantify each amino acid present.
Persister assay. Overnight cultures in liquid 0.4% glucose M9 minimal medium were
grown as described in the Lawn assay for quiescence section, above. Cultures were then
diluted 20-fold into 10 ml of fresh 0.2% glucose M9 minimal medium (A600 = 0.1, ~108
CFU/ml) in both the presence and absence of ampicillin sodium salt (100 µg/ml, SigmaAldrich, Inc.). The cultures were incubated with shaking at 37°C and viable counts on
LB agar plates were determined at 2, 4, 6, and 24 h. To determine whether cells surviving
at 24 h in the presence of ampicillin were persister cells or ampicillin resistant mutants, 5
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ml were washed free of ampicillin by centrifuging at 16,000 x g for 3 min, washing twice
in 5 ml of fresh 0.2% glucose M9 minimal medium, and resuspending in 5ml of LB
broth. Each 5 ml culture was then grown for 2.25 h at 37°C with shaking in a 125 ml
tissue culture bottle at which time a sample was taken for viable counts. Ampicillin
sodium salt (100 µg/ml) was then added to each culture and 4 h later a sample was again
taken for viable counts on LB agar plates. Plates were incubated at 37°C for 18 h prior to
counting.
Photography. Images of agar plates were made using a BIO-RAD Molecular Imager®
Gel Doc™ XR+ System with Image Lab™ Software.
Statistics. Means and standard deviations of data presented in Table 4 and in Figures 4,
5, 7, 8, and 9 were compared by a two-tailed Student t test. P values of ≤ 0.05 were
interpreted as indicating a significant difference.
Results
E. coli CFT073, a UPEC strain, and E. coli Nissle 1917, a closely related probiotic
strain, grow in liquid glucose M9 minimal medium, but fail to grow on glucose M9
minimal medium agar plates. We were attempting to determine which colicins and
microcins are active on the sequenced E. coli CFT073, a phylogenetic group B2
multilocus sequence type 73 (ST73) UPEC strain (20, 21), and the closely related ST73
probiotic strain, E. coli Nissle 1917 (22). As expected, we found that after overnight
incubation at 37°C, both strains formed lawns of growth on 0.2% glucose M9 minimal
medium agar plates (hereafter called glucose plates) when either 107 or 108 CFU were
plated from an overnight 0.4 % glucose M9 minimal medium liquid culture.
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Unexpectedly, however, when 106 CFU or fewer were plated on glucose plates they
failed to form lawns or colonies after 24 h and 48 h of incubation at 37°C. This result
was unusual in that a number of human commensal E. coli strains, including MG1655,
HS, F-18, EFC1, and EFC2 (Table 1), and the O157:H7 strain E. coli EDL933 (Table 1)
tested at 105 CFU grew as lawns on the glucose plates after 24 hours at 37°C and viable
counts could be determined for each strain on glucose plates (not shown). That all the E.
coli strains tested for growth on glucose plates are spontaneous streptomycin resistant
mutants (Table 1), but only E. coli CFT073 and E. coli Nissle 1917 failed to form lawns
on glucose plates seeded with ≤ 106 CFU, makes it highly unlikely that point mutations in
ribosomal proteins play a role in the observed lack of growth.
Toothpicking a colony of E. coli MG1655 grown on glucose plates onto glucose
plates seeded with 105 or 106 CFU of E. coli CFT073 or E. coli Nissle 1917 resulted in E.
coli CFT073 and E. coli Nissle 1917 growth around the toothpicked colonies after
incubation for 24 h at 37°C, but not anywhere else on the plates (Fig. 1A) (toothpicking
colonies in this manner is a normal procedure used in colicin and microcin testing). No
growth was observed around toothpicked E. coli MG1655 colonies grown on glucose
plates that had not been seeded with E. coli CFT073 or E. coli Nissle 1917 (not shown).
These results suggested that toothpicked E. coli MG1655 was secreting a molecule(s)
(hereafter called the MG1655 stimulus ) as it grew on glucose plates that was either
preventing E. coli CFT073 and E. coli Nissle 1917 death or was preventing them from
entering a “quiescent” state. Incubating the plates that had been seeded with 105 CFU of
E. coli CFT073 or E. coli Nissle 1917 for 48 h at 37°C resulted in a much larger region of
growth around the toothpicked E. coli MG1655 than at 24 h (Fig. 1B), suggesting that
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cells could be stimulated to grow after 24 hours of incubation, thereby favoring the
quiescence hypothesis and suggesting either that the MG1655 stimulus was diffusible
and active at a very low concentration or that growing E. coli CFT073 and E. coli Nissle
1917 also secreted the stimulus . Also, when glucose plates seeded with 105 or 106 CFU
of E. coli CFT073 or E. coli Nissle 1917 were incubated for 24 h at 37°C prior to
toothpicking E. coli MG1655 to those plates, E. coli CFT073 and E. coli Nissle 1917
growth was observed surrounding the toothpicked E. coli MG1655 colonies after an
additional 24 h incubation at 37°C (not shown). Therefore, many of the E. coli CFT073
and E. coli Nissle 1917 cells were alive, but “quiescent” on glucose plates for at least 24
hours. Importantly, quiescence is not observed when Difco Bacto agar is used in glucose
plates instead of Difco Agar Noble, suggesting impurities in the former allow growth. It
should be noted that at the present time we do not know whether it is alive or dead E. coli
MG1655 cells that are the source of the stimulus as the toothpicked cells grow on the
glucose plates. Also, it should be mentioned that E. coli CFT073 and E. coli Nissle 1917
quiescence is not dependent on using 0.2% glucose M9 minimal medium agar plates,
identical results were obtained using 0.4% glucose M9 minimal medium agar plates (not
shown).
Testing additional E. coli strains for quiescence on glucose plates. E. coli can be
separated into four major phylogenetic groups (A, B1, B2 and D) and two additional
phylogenetic groups that have recently been defined: phylogenetic group AxB1,
containing strains that derive most of their ancestry from A and B1, and phylogenetic
group ABD, containing a heterogeneous set of strains with multiple sources of ancestry
(23). Thirty E. coli strains representing various multilocus sequence types (ST) of the 6
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phylogenetic groups, i.e. two ST10 and two ST453 strains from phylogenetic group A;
two ST58, two ST410, and two ST101 strains from phylogenetic group B1; two ST73,
two ST95, and two ST131 strains from phylogenetic group B2; two ST69, two ST354,
and two ST648 strains from phylogenetic group D; two ST90 and two ST642 strains from
phylogenetic group AxB1; two ST62 and two ST117 strains from phylogenetic group
ABD were grown in liquid glucose M9 minimal medium and the 30 strains were tested
for the ability to grow on glucose plates seeded with 105 CFU and to respond to the
MG1655 stimulus. Of the 30 strains, 2 failed to grow on glucose plates and those strains
responded to the MG1655 stimulus. The 2 strains that failed to grow on glucose plates
were ST73 strains. ST73 is a very common UPEC lineage, accounting for 11% and
16.6% of UPEC isolated from patients in 2 recent studies (24, 25). Importantly, E. coli
CFT073 and E. coli Nissle 1917 are also ST73 strains.
Testing additional ST73 strains for quiescence on glucose plates. Since it appeared
that quiescence on glucose agar plates may be characteristic of the ST73 lineage, 40
additional ST73 strains were tested for the ability to grow on glucose plates seeded with
105 CFU and to respond to the MG1655 stimulus . Two of the strains failed to grow
overnight in liquid glucose M9 minimal medium, but of the 38 strains that grew, 30
(78.9%) failed to grow on glucose plates, but responded to the MG1655 stimulus.
Therefore, the vast majority of ST73 strains, a major UPEC lineage (24, 25), are
quiescent on glucose plates.
Testing 40 UPEC strains isolated from community acquired UTIs in Denmark for
quiescence on glucose plates. Forty randomly selected UPEC strains isolated from
community acquired UTIs in Denmark were tested for the ability to grow on glucose
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plates seeded with 105 CFU and to respond to the MG1655 stimulus. Of the 40 UPEC
strains tested, all grew overnight in liquid glucose M9 minimal medium, but 9 failed to
grow on glucose plates (22.5%) unless stimulated to do so by the MG1655 stimulus.
Three of the 9 strains that failed to grow on glucose plates were ST73 strains (5 of the 40
UPEC strains tested [12.5%] were ST73) and 3 of the 9 strains that failed to grow on
glucose plates were ST141 strains (3 of the 40 UPEC strains tested were ST141 strains
[7.5%], a group not represented in the original 30 strains tested). The 3 remaining strains
that failed to grow on glucose plates (ST104, ST394, and ST998) were not represented in
the original 30 strains tested and each was represented only once among the 40 UPEC
strains tested (2.5% each) . It therefore appears that the inability to grow on glucose
plates, yet respond to the MG1655 stimulus, is not limited to the ST73 group.
The inability of E. coli CFT073 to grow on minimal agar plates is not limited to
glucose as sole carbon source. E. coli CFT073 was tested for the ability of 105 CFU to
grow on M9 minimal agar plates containing 0.2% acetate, arabinose, fructose, fucose,
galactose, gluconate, glycerol, N-acetylglucosamine, maltose, mannose, ribose, and
xylose as sole carbon sources. E. coli CFT073 grew overnight in liquid M9 minimal
medium containing each carbon source, but 105 CFU only grew as a lawn on agar plates
containing glycerol, ribose, and xylose as sole carbon sources (Fig. 2). On those plates
that E. coli CFT073 failed to grow, it responded to the MG1655 stimulus.
Human urine, a cocktail mimicking the amino acid composition of human urine,
and a cocktail mimicking amino acids present in a concentrated E. coli MG1655
culture supernatant prevent E. coli CFT073 quiescence on glucose plates. We
normally toothpick a colony of E. coli MG1655 to a glucose plate as a source of the
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MG1655 stimulus, suggesting that the stimulus is secreted on the plate as E. coli
MG1655 grows. However, no stimulus activity was found when 5 µl or 20 µl of a cellfree supernatant derived from an overnight liquid glucose M9 minimal medium culture of
E. coli MG1655 was placed on a glucose agar plate seeded with 105 CFU of E. coli
CFT073 or E. coli Nissle 1917. Stimulus activity was observed when 5 µl of a cell-free
supernatant derived from a 50-fold concentrated E. coli MG1655 culture that had been
incubated overnight at 37°C (see Materials and Methods) was placed on a glucose agar
plate seeded with 105 CFU of E. coli CFT073 (Fig. 3A). Analysis of one such E. coli
MG1655 cell-free supernatant revealed the presence of a number of unknown small
molecules and 14 amino acids (Table 3). Importantly, 5 µl of an amino acid cocktail
identical in composition to the amino acids in the 50-fold concentrated E. coli MG1655
supernatant displayed similar stimulus activity to 5 µl of the 50-fold concentrated
supernatant (Fig. 3B). A cell-free supernatant derived from a 50-fold concentrated E. coli
CFT073 culture was nearly identical to the E. coli MG1655 supernatant in amino acid
composition, but in addition contained aspartic acid (Table 3). As expected, 5 µl of the
E. coli CFT073 cell-free supernatant also displayed stimulus activity on glucose plates
seeded with 105 CFU of E. coli CFT073. Perhaps even more importantly, 5 µl of sterile
filtered human urine collected from one of us and 5 µl of a cocktail mimicking the amino
acid composition of human urine ([26] and Table 3) both displayed stimulus activity on
glucose plates seeded with 105 CFU of E. coli CFT073 (Fig. 3C and 3D).
Lysine, methionine, and tyrosine involvement in preventing quiescence. 1.0 mM
solutions of each of the 20 standard L-amino acids were prepared and 5 µl of each was
tested on glucose plates seeded with 105 CFU of E. coli CFT073. None displayed
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stimulus activity. However, testing 5 µl of single amino acid deletions from the amino
acid cocktail mimicking the concentrations of amino acids in urine (Table 3) and in the
50-fold concentrated E. coli MG1655 supernatant (Table 3) revealed that cocktails
missing lysine, methionine, and tyrosine failed to stimulate. Furthermore, although 5 µl
of 1.0 mM lysine alone, 1.0 mM methionine alone, and 1.0 mM tyrosine alone failed to
stimulate (not shown), 5 µl of mixtures of 1.0 mM each of lysine, methionine, and
tyrosine (Fig. 3E) were about as stimulatory for growth of E. coli CFT073 on glucose
plates as either the E. coli MG1655 amino acid cocktail (Fig. 3B) or the amino acid
cocktail mimicking human urine (Fig. 3D). 5 µl of mixtures of 1.0 mM each of Dlysine, D-methionine, and D-tyrosine failed to stimulate (not shown), demonstrating the
importance of the L- forms of the 3 amino acids in preventing quiescence. Mixtures of
1.0 mM each of lysine and methionine (Fig. 3F) and 1.0 mM each of lysine and tyrosine
(Fig. 3G) also stimulated E. coli CFT073 growth on glucose plates, although stimulation
of E. coli CFT073 growth by the mixture of lysine and tyrosine was minimal (Fig. 3G).
A mixture of 1.0 mM each of methionine and tyrosine failed to stimulate E. coli CFT073
growth (Fig. 3H). In summary, E. coli MG1655 is not required to provide the stimulus
that prevents E. coli CFT073 quiescence, a mixture of lysine, methionine, and tyrosine,
found in concentrated 50-fold concentrated E. coli MG1655 supernatants, is just as
effective.
E. coli CFT073 and E. coli Nissle 1917, but not E. coli MG1655 generate high levels
of persister cells in liquid glucose M9 minimal medium. Persister cells are dormant
cells formed in normal microbial populations as small subpopulations (10-3 to 10-4 %) that
are highly tolerant to antibiotics, but upon regrowth in the absence of antibiotics regain
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full sensitivity (11). Persister cells appear to play a role in the ability of bacteria causing
chronic infections to withstand antibiotic treatment (11). Because E. coli CFT073
becomes quiescent on glucose plates and quiescence is reminiscent of persistence, we
wondered whether E. coli CFT073 generates a high level of persister cells in liquid
glucose M9 minimal medium. 0.4% Glucose M9 minimal medium grown overnight
cultures of E. coli CFT073 were diluted 20-fold into fresh 0.2% glucose M9 minimal
medium (A600=0.1, ~108 CFU/ml) containing or lacking ampicillin (100 µg/ml) and
viable counts were followed for 24 hours at 37°C (Fig. 4). During the first 4 h of
incubation, viable counts in the E. coli CFT073 cultures decreased 10-fold in both the
presence and absence of ampicillin, i.e. from 108 CFU/ml to 107 CFU/ml. No further
death occurred between 4 h and 6 h in the absence of ampicillin, and by 24 h E. coli
CFT073 had grown to almost 109 CFU/ml (Fig. 4). In contrast, between 4 h and 6 h in
the presence of ampicillin, viable counts decreased almost an additional 10-fold to about
106 CFU/ml in the E. coli CFT073 cultures (Fig. 4). However, there was little further E.
coli CFT073 death in the presence of ampicillin between 6 h and 24 h (Fig. 4), suggesting
the possibility that the survivors (~0.7%) at 24 h might be persisters. Therefore, at 24 h,
E. coli CFT073 cultures containing ampicillin were centrifuged, washed free of the
antibiotic, resuspended in LB broth, and grown at 37°C for 2.25 h to 108 CFU/ml, at
which time ampicillin was added (100 µg/ml). Four hours later, viable counts in the E.
coli CFT073 LB broth cultures had dropped to 104 CFU/ml, suggesting that the vast
majority of cells that survived ampicillin treatment in liquid glucose M9 minimal medium
were indeed persister cells, still fully sensitive to ampicillin. Much like E. coli CFT073,
E. coli Nissle 1917 generated a high level of persister cells in liquid glucose minimal
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medium, i.e. about 2.6% at 24 h (Table 4) and the cells were still sensitive to ampicillin
as described above.
Unlike E. coli CFT073 and E. coli Nissle 1917, when E. coli MG1655 overnight
cultures were diluted 20-fold into fresh 0.2% glucose M9 minimal medium, viable counts
increased immediately in the absence of ampicillin and in the presence of ampicillin
decreased continuously for 6 h to a level of about 103 CFU/ml (10-3 %) and remained at
that level at 24 h (Fig. 4). The E. coli MG1655 survivors in cultures containing
ampicillin were also persister cells, i.e. when regrown in LB broth without ampicillin,
they regained sensitivity. Therefore, when grown in liquid glucose M9 minimal medium,
E. coli CFT073 and E. coli Nissle 1917 cultures generated about 1000-fold more
persister cells than E. coli MG1655 cultures.
E. coli CFT073 generates a low level of persister cells in liquid glucose M9 minimal
medium containing amino acids. Since amino acids reversed E. coli CFT073
quiescence on glucose plates, we were interested in determining whether addition of a
mixture of the 20 standard L-amino acids (100 µg/ml each) to cultures of E. coli CFT073
grown in glucose M9 minimal medium in the absence of amino acids would generate
fewer persister cells. As shown in Fig. 5, in the presence of the amino acid mixture and
in the absence of ampicillin, E. coli CFT073 viable counts increased immediately,
reaching stationary phase within 4 h. Importantly, in the presence of both the amino acid
mixture and ampicillin, E. coli CFT073 viable counts decreased continuously for 24 h to
a level of about 5 x 103 CFU/ml (Fig. 5). That the survivors at 24 were persister cells
was shown by the fact that when regrown in LB broth without ampicillin, they regained
sensitivity, as described above. In the absence of amino acids and in the presence of
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ampicillin, E. coli CFT073 persister cells were again generated at a level of about 106
CFU/ml (Fig. 5). Therefore, in the presence of amino acids, about 100-fold fewer E. coli
CFT073 persister cells were generated than in their absence (Fig. 5).
Isolation and characterization of E. coli CFT073 mini-Tn5 mutants that grow on
glucose plates. Since E. coli CFT073 grows overnight in liquid glucose M9 minimal
medium, but not on glucose plates, we thought it possible that expression of one or more
genes on glucose plates, but not in liquid glucose cultures might be responsible. If so,
knockout of the responsible gene(s) would result in growth on glucose plates. Therefore,
E. coli CFT073 mini-Tn5 Km (kanamycin) mutants were generated by random
insertional mutagenesis (see Materials and Methods) and any mutant that grew as a lawn
on glucose plates was confirmed by transferring the insertion into a fresh E. coli CFT073
background and retesting it for growth on glucose plates (see Materials and Methods).
Five confirmed non-quiescent mini-Tn5 Km mutants were isolated from
approximately 2000 mutants tested. E. coli CFT073 and the mini-Tn5 Km mutants were
grown overnight in liquid glucose M9 minimal medium and viable counts were made on
both glucose plates and LB agar plates. As expected, E. coli CFT073 assayed from the
overnight cultures failed to grow on the glucose plates when ≤ 106 CFU were plated, but
when assayed on LB agar viable counts showed that the cultures contained ~109 CFU/ml.
In contrast, when assayed on either glucose plates or LB agar plates the 5 mini-Tn5 Km
mutant cultures each contained about ~109 CFU/ml. It therefore appears that the miniTn5 Km insertion in each of the 5 genes completely prevented quiescence on glucose
plates.
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The mini-Tn5 Km insertions that resulted in mutants able to grow on glucose plates
after transfer into a fresh E. coli CFT073 background were in the following 5 genes (Fig.
6): (i) sdhA: encodes the succinate-binding flavoprotein subunit of succinate
dehydrogenase (27). As a consequence, the E. coli CFT073 sdhA mutant fails to grow on
succinate as sole carbon source, but grows normally on glucose. (ii) gnd: encodes 6phosphogluconate dehydrogenase which functions in the oxidative branch of the pentose
phosphate pathway to synthesize ribulose-5-phosphate from 6-phosphogluconate (28,
29). Ribulose-5-phosphate is an essential precursor in the synthesis of FAD, nucleotides,
and LPS. (iii) zwf: encodes glucose-6-phosphate dehydrogenase, which functions in the
oxidative branch of the pentose phosphate pathway and the Entner-Doudoroff pathway
when E. coli is grown on glucose (28, 29). (iv) pykF: encodes pyruvate kinase, which
converts phosphoenolpyruvate to pyruvate in the Embden-Meyerhof-Parnas pathway
(30). (v) gdhA: encodes glutamate dehydrogenase, which catalyzes the amination of αketoglutarate to glutamate (31).
It might be argued that the mini- Tn5 Km insertions in the identified genes are not the
cause of non-quiescence, but that non-quiescence is caused by downstream polarity
effects. Indeed, the mini-Tn5 Km transposon used in the present study has strong
transcription termination sequences flanking both ends of the kanamycin resistance gene
(17). However, the intergenic number of nucleotides and nucleotide sequences between
gnd and the immediate downstream ugd, between pykF and the immediate downstream
lpp, and between zwf and the immediate downstream edd are identical in E. coli MG1655
and E. coli CFT073 (GenBank accession numbers U00096.3 and AE014075.1) (21, 32).
Moreover, in E. coli MG1655 and therefore in E. coli CFT073, there is a strong
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presumptive promoter between gnd and ugd (33) and in E. coli MG1655 and therefore in
E. coli CFT073 both lpp and edd have their own experimentally identified promoters
(33). It is therefore highly likely that non-quiescence is caused by interrupting gnd, pykF,
and zwf, and not by downstream polarity effects. Also, in E. coli CFT073, gdhA is
immediately upstream of c2163, which is transcribed in the opposite direction to gdhA
(21), making it highly unlikely that non-quiescence caused by the insertion in gdhA is due
to downstream polarity. Finally, although in E. coli MG1655 the number of nucleotides
between the end of the sdhCDAB operon and the beginning of the immediately
downstream sucABCD operon is 241 nucleotides less than that in E. coli CFT073
(GenBank accession numbers U00096.3 and AE014075.1) (31, 32), the experimentally
identified E. coli MG1655 sucABCD promoter is identical in sequence to the presumptive
E. coli CFT073 sucABCD promoter and the nucleotide sequence between the 3’ end of
the promoter and the start of sucA transcription is identical in both strains (21, 32, 33). It
is therefore highly unlikely that non-quiescence caused by the insertion in sdhA is due to
a downstream polarity effect on the sucABCD operon in E. coli CFT073.
Of the 5 mini-Tn5 Km mutants, only E. coli CFT073 sdhA and gdhA generate low
levels of persister cells. Since the 5 E. coli CFT073 mini-Tn5 Km mutants were nonquiescent on glucose plates, we wondered whether they would generate fewer persister
cells than E. coli CFT073 in glucose M9 minimal medium. Indeed, the E. coli CFT073
sdhA and gdhA mutants, which began growth shortly after dilution of overnight cultures
into fresh glucose M9 minimal medium, generated only about 5 x 102 persister cells/ml,
i.e. about 2000-fold fewer persister cells in the presence of ampicillin than wildtype E.
coli CFT073 (Figs. 7 and 8). In contrast, the E. coli CFT073 gnd, pykF, and zwf mutants
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generated about the same level of persister cells as E. coli CFT073 (Table 4), suggesting
that quiescence and persistence are not identical phenomena.
E. coli CFT073 persistence and quiescence require a complete TCA cycle. Succinate
dehydrogenase converts succinate to fumarate (Fig. 6). The fact that the E. coli CFT073
sdhA mutant generated about 2000-fold fewer persister cells than E. coli CFT073
suggested the possibility that the ability to make fumarate from succinate was required
for persister cell formation. To test that possibility, E. coli CFT073 sdhA cultures were
grown overnight in liquid 0.4% glucose M9 minimal medium in the presence and absence
of fumarate (200 µg/ml) and persister cell assays were performed in 0.2% glucose M9
minimal medium in the presence of fumarate for cultures grown with fumarate and in the
absence of fumarate for cultures grown without fumarate. In the presence of fumarate
and ampicillin, E. coli CFT073 sdhA cultures generated between 105 and 106 CFU/ml
persister cells (Fig. 9), much like E. coli CFT073 (Figs. 4, 5, 7, and 8), whereas in the
absence of fumarate and the presence of ampicillin, E. coli CFT073 sdhA cultures
generated only 5 x 102 CFU/ml persister cells (Fig. 9). Therefore, allowing completion
of the TCA cycle by supplying E. coli CFT073 sdhA with fumarate rescued its ability to
generate a high level of persister cells, suggesting that a complete oxidative TCA cycle is
required for maximal persister cell generation
Since persister cell generation required a complete TCA cycle, we wondered whether
the same was true of quiescence. To that end, E. coli CFT073 sdhA was grown overnight
in liquid 0.4% glucose M9 minimal medium in the presence and absence of fumarate
(200 µg/ml). Glucose plates containing fumarate (200 µg/ml) were seeded with 105 CFU
of E. coli CFT073 sdhA grown in the presence of fumarate or 105 CFU of E. coli CFT073
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sdhA grown in the absence of fumarate and were incubated at 37°C for 24 h. In both
cases, E. coli CFT073 sdhA failed to grow, but responded to 5 µl of a 1.0 mM mixture of
lysine, methionine, and tyrosine (Fig. 10A), not only suggesting that the presence of
fumarate in the glucose plate rescued quiescence, but that quiescence was generated on
the glucose plate and not in the liquid culture. As a control, glucose plates without
fumarate were seeded with 105 CFU of E. coli CFT073 sdhA grown overnight in liquid
glucose M9 minimal medium in the absence of fumarate and plates were incubated at
37°C for 24 h. As expected, a lawn of E. coli CFT073 sdhA growth was observed on the
glucose plates under these conditions (Fig. 10B). Therefore, not only does fumarate
rescue the ability of E. coli CFT073 sdhA to generate a high level of persisters in liquid
glucose M9 minimal medium in the presence of ampicillin (Fig. 9), it rescues the ability
of E. coli CFT073 sdhA to enter the quiescent state on glucose plates. As a side note,
rescue by fumarate, obviating the need for succinate dehydrogenase, further implicates
the mini-Tn5 Km insertion and not a downstream polarity effect as the cause of nonquiescence and reduced persistence of the sdhA mutant.
The E. coli CFT073 original clinical isolate is quiescent on glucose plates, but
generates very few persister cells in liquid glucose M9 minimal medium. As we were
completing this study, we became aware of a paper reporting that the sequenced E. coli
CFT073 (22), which has long been considered to be the wildtype strain, has a 5 bp
duplication in rpoS which results in a truncated, non-functional RpoS (34). RpoS, often
referred to as the alternative sigma factor σS, directs RNA polymerase to transcribe genes
involved in the E. coli general stress response, e.g. acid resistance (35). The E. coli
CFT073 used in this study does indeed have the 5 bp duplication in rpoS (Leatham-
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Jensen MP, unpublished results). We therefore obtained and tested the original clinical
isolate of E. coli CFT073, which has a wildtype rpoS gene (34), for quiescence and
persister cell formation. The E. coli CFT073 original clinical isolate is indeed quiescent
on glucose plates and responds to lysine, methionine, and tyrosine like the rpoS mutant
used here (Fig. 11), but generates about 2000-fold fewer persister cells in liquid glucose
M9 minimal medium than the rpoS mutant used in the present study (Table 4).
Therefore, it appears that the mutant rpoS gene is necessary for the high level of
persistence observed, but is not necessary for E. coli CFT073 quiescence on glucose
plates.
Discussion
The data presented here show that the uropathogen E. coli CFT073 and the probiotic
E. coli Nissle 1917, both ST73 strains belonging to phylogenetic group B2, are quiescent
on glucose plates seeded with ≤ 106 CFU, as are 35/45 (77.8%) additional ST73 strains
tested. ST73 is a very common UPEC lineage (24, 25). In contrast, of 4 phylogenetic
group A, 6 phylogenetic group B1, 6 phylogenetic group D, 4 phylogenetic group ABD,
and 4 phylogenetic group AxB1 strains, none (0/24) were quiescent. However, 9 of 40
randomly selected UPEC strains isolated from community acquired UTIs in Denmark
(22.5%) were quiescent on glucose plates (3/5 ST73 strains, 3/3 ST141 strains, 1/1 ST104
strain, 1/1 ST394 strain, and 1/1 ST998 strain). Thus quiescence on glucose plates is
common among UPEC isolates and is not restricted to one ST type.
The data presented here also show that the E. coli CFT073 original clinical isolate,
like the E. coli CFT073 strain used here, which has a 5 bp duplication in rpoS that
inactivates the gene (33), is quiescent on glucose plates (Fig. 11), but unlike the E. coli
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CFT073 strain used here, generates a low level of persister cells in the presence of
ampicillin (Table 4). Therefore, quiescence and persistence, while similar in some
respects, i.e. both are prevented by amino acids and both require a complete oxidative
TCA cycle, are not identical. In addition, quiescence and persistence differ in that of the
5 E. coli CFT073 mini-Tn5 non-quiescent mutants isolated in the present study (gdhA,
gnd, pykF, sdhA, and zwf), only 2 (gdhA and sdhA) were deficient in persister cell
formation (Table 4).
It has been reported, as reported here for E. coli CFT073, that deleting rpoS in E. coli
K-12 also dramatically increases formation of persister cells in the presence of ampicillin
(36). Why then, does E. coli Nissle 1917, which has a wildtype rpoS gene (LeathamJensen MP, unpublished results and [36]), generate at least as high a level of persister
cells as E. coli CFT073 (Table 4)? E. coli Nissle 1917 would be expected to be acid
resistant since a wildtype rpoS gene is required for acid resistance; however, it has been
reported to be extremely acid sensitive (37). This suggests the possibility that the E. coli
Nissle 1917 rpoS gene may be poorly expressed or that RpoS is rapidly degraded, which
is consistent with its generating as high a level of persister cells as the E. coli CFT073
rpoS mutant used here. Many E. coli strains contain wildtype rpoS genes that are
expressed poorly relative to other strains (38).
While it is unclear as to why E. coli CFT073 gnd and zwf mutants are non-quiescent
on glucose plates, the reason E. coli K-12 gnd and zwf mutants grow on glucose as sole
carbon source is known (29, 30). When E. coli K-12 is grown on glucose as sole carbon
source, glucose-6-phosphate dehydrogenase, encoded by zwf, and 6-phosphogluconate
dehydrogenase, encoded by gnd, are used for the synthesis of ribulose-5-phosphate via
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the oxidative branch of the pentose phosphate pathway (Fig. 6 and [28, 29]). Ribulose-5phosphate is an essential precursor in the synthesis of FAD, nucleotides, and LPS.
Furthermore, both enzymes generate NADPH for biosynthesis. It might therefore seem
surprising that mutations in gnd and zwf allow growth on glucose as sole carbon source
(Fig. 6). However, null mutations in gnd and zwf in E. coli K-12 do not significantly
affect their growth on glucose because the non-oxidative branch of the pentose phosphate
pathway runs backwards in these mutants, generating ribulose-5-phosphate from
fructose-6-phosphate and glyceraldehyde-3-phosphate (Fig. 6 and [28, 29]) and the
necessary NADPH for biosynthesis by increased flux through the TCA cycle (28, 29). It
is therefore possible that for unknown mechanistic reasons the oxidative branch of the
pentose phosphate pathway operates minimally during E. coli CFT073 quiescence,
generating little ribulose-5-phosphate, but that the gnd and zwf mutations cause the nonoxidative branch to run backwards and flux through the TCA cycle to increase,
generating a sufficient level of ribulose-5-phosphate and NADPH to prevent quiescence.
This scenario is consistent with the observation that ribose and xylose, both of which are
metabolized in the non-oxidative branch of the pentose phosphate pathway, prevent
quiescence when used as sole carbon sources (Fig. 2).
The E. coli CFT073 pykF mutant also grows on glucose as sole carbon source. The
pykF gene encodes pyruvate kinase which converts PEP to pyruvate (Fig. 6). There is a
second pyruvate kinase, encoded by pykA, but during E. coli K-12 growth in glucose
minimal medium, it contributes little to total pyruvate kinase activity (39). Moreover, in
the complete absence of pyruvate kinase, pyruvate can still be generated in E. coli K-12
both through glucose transport via the phosphotransferase transport system (PTS) (40)

109
and the Entner-Doudoroff pathway (31, 38). Therefore, it is not surprising that the nonquiescent E. coli CFT073 pykF mutant can grow on glucose as sole carbon source, but
why is it non-quiescent? It has been suggested that pykF mutants contain increased
intracellular levels of PEP (30). If PEP, a common precursor in lysine, methionine, and
tyrosine biosynthesis (Fig. 6), is increased in the E. coli CFT073 pykF mutant growing on
glucose plates, sufficient intracellular levels of the 3 amino acids might be generated to
stimulate growth and prevent quiescence.
The gdhA gene encodes glutamate dehydrogenase, which converts α-ketoglutarate to
glutamate (Fig. 6). It is known that E. coli K-12 gdhA mutants grow on glucose as sole
carbon source in the absence of glutamate dehydrogenase because glutamate can also be
synthesized via the sequential action of glutamine synthetase and glutamate synthase (31,
41). Therefore, it appears that the switch from producing glutamate via glutamate
dehydrogenase to producing it via glutamine synthetase and glutamate synthase in E. coli
CFT073 somehow prevents quiescence. It has been estimated that 88% of assimilated
nitrogen in E. coli, including the nitrogen in amino acids, originates from glutamate and
the remaining 12% from glutamine (42). Perhaps glutamate and glutamine are in higher
concentrations in gdhA mutants growing on glucose, which could contribute to higher
intracellular levels of lysine, methionine, and tyrosine and as a consequence, nonquiescence.
E. coli K-12 succinate dehydrogenase mutants grow on glucose as sole carbon source
because it is not necessary for the TCA cycle to function as a complete oxidative cycle to
achieve growth (43). In fact, when growing on excess glucose, the E. coli K-12 TCA
cycle operates in branched mode, i.e. an oxidative branch which runs from citrate to α-
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ketoglutarate and a reductive branch which runs backwards from oxaloacetate to
succinyl-CoA (Fig. 6 and [43]). Succinate dehydrogenase is not necessary under these
conditions and both branches serve biosynthetic functions. As a result, neither branch is
used for ATP generation (42). ATP is generated from glycolysis and via the
phosphotransacetylase (pta)-acetate kinase (ackA) pathway producing acetate in the
process (Fig. 6 and [43]). Therefore, it appears likely that forcing the TCA cycle to
operate in branched mode somehow prevents E. coli CFT073 quiescence. In branched
mode, the TCA cycle is unable to regenerate oxaloacetate and therefore gets oxaloacetate
from PEP via PpC (Fig. 6). Perhaps under these conditions sufficient oxaloacetate is
generated via Ppc to increase intracellular levels of lysine and methionine (Fig. 6) and
consequently, prevent quiescence. In this vein, addition of fumarate to glucose plates,
results in return of the E. coli CFT073 sdhA mutant to quiescence, presumably by
rescuing the ability of the TCA cycle to operate as a complete oxidative cycle. It should
also be noted that an E. coli CFT073 succinate dehydrogenase mutant (sdhB) has been
shown to be severely attenuated in an ascending mouse UTI model (44), indicating a
possible link between in vitro non-quiescence and reduced pathogenesis in vivo.
While it is clear why the E. coli CFT073 mini-Tn5 Km non-quiescent mutants are
capable of growth using glucose as sole carbon source, it is not mechanistically clear as
to why the mutations prevent quiescence on glucose plates. Possibly, a gene encoding a
regulator whose synthesis or activity is inhibited by various combinations of lysine,
methionine, and tyrosine, promotes quiescence. The regulator would presumably be
expressed or active in the vast majority of E. coli CFT073 cells on glucose plates, but in
relatively few cells of the E. coli CFT073 mini-Tn5 Km non-quiescent mutants due to the
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complex metabolic changes that occur in such mutants (28, 29, 30, 39, 45, 46). If
expression and activity of a specific E. coli CFT073 regulator is critical for generation of
quiescence, much as toxin/antitoxin systems appear to be critical in generating persister
cells (11, 47), screening more mini-Tn5 Km mutants may lead to its identification.
Furthermore, it is unclear as to why the E. coli CFT073 gdhA and sdhA mutants generate
far fewer persister cells than the gnd, zwf, and pykF mutants (Table 4). Metabolic flux
analysis (28, 29, 30) and RNA-seq (48) may prove useful in this regard.
How might the findings reported here be relevant to recurrent UTI infections and how
might its relevance be tested? It is known that E. coli CFT073 utilizes amino acids and
small peptides as carbon sources and a complete oxidative TCA cycle to infect the mouse
urinary tract (44, 49) and appears to import small peptides to grow in mouse urine in vitro
(44). UPEC may also use peptides for growth in vivo in urine during human UTI (50). It
is also known that E. coli CFT073 can infect mouse superficial facet cells and form
biofilm-like intracellular communities (IBCs) (51) and therefore most likely can form
Quiescent Intracellular Reservoirs (QIRs) in underlying transitional cells. Furthermore, it
seems reasonable that QIRs surviving antibiotic treatment serve as a reservoir for
recurrent UTI infection after withdrawal of antibiotics (8, 10), i.e. as transitional cells
undergo apoptosis and released QIRs resume growth in urine using peptides and amino
acids in the process (44, 49, 50). However, it should be noted that the role of QIRs in
recurrent UTI is still controversial. It has recently been shown that UPEC strains isolated
from the feces and urine of female patients during recurrent episodes are identical,
consistent with the possibility that recurrent UTI is caused by UPEC strains that colonize
the intestine, but periodically move to the urinary tract (52). Nevertheless, if the in vitro
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quiescence reported here mimics the QIR state and if QIRs are a major source of
recurrent UTI, the E. coli CFT073 non-quiescent mutants we’ve isolated should be less
able to establish QIRs in the mouse bladder and therefore be less able to cause recurrent
UTI. If so, it is possible that drugs designed to inactivate the enzymes encoded by gdhA,
gnd, pykF, sdhA, and zwf might be effective in limiting recurrent urinary tract infection.
On the other hand, if the in vitro persistence state mimics the QIR state in mouse bladder
cells, only the E. coli CFT073 gdhA and sdhA mutants should be less able to cause
recurrent UTI and if so, drugs designed to inactivate the enzymes encoded by gdhA and
sdhA might be effective in limiting recurrent urinary tract infection

A recurrent UTI

mouse model is available for testing these hypotheses (8).
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Table 1. Bacterial Strains
E. coli strain

Genotype/phenotype

Referred to in text as:

CFT073 StrR

Spontaneous

CFT073

Source/Reference
(53)

streptomycin resistant
mutant of CFT073,
has 5 bp duplication
in rpoS
CFT073 StrR mini-

mini-Tn5 Km

Tn5 Km::gdhA

glutamate

CFT073 gdhA

This study

CFT073 gnd

This study

CFT073 pykF

This study

CFT073 sdhA

This study

dehydrogenase mutant
of CFT073 StrR
CFT073 StrR mini-

mini-Tn5 Km

Tn5 Km::gnd

6-phosphogluconate
dehydrogenase mutant
of CFT073 StrR

CFT073 StrR mini-

mini-Tn5 Km

Tn5 Km::pykF

pyruvate kinase
mutant of CFT073
StrR

CFT073 StrR mini-

mini-Tn5::Km

Tn5 Km::sdhA

flavoprotein subunit
of succinate
dehydrogenase
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mutant of CFT073
StrR
CFT073 StrR mini-

mini-Tn5::Km

Tn5 Km::zwf

glucose-6-phosphate

CFT073 zwf

This study

dehydrogenase
mutant of CFT073
StrR
wildtype CFT073

Nissle 1917 StrR

original clinical

CFT073 original

isolate

clinical isolate

spontaneous

Nissle 1917

(57)

MG1655

(54)

HS

(55)

EFC1

(55)

(34)

streptomycin resistant
mutant of Nissle 1917
MG1655 StrR

spontaneous
streptomycin resistant
mutant of MG1655

HS StrR

spontaneous
streptomycin resistant
mutant of HS

EFC1 StrR

spontaneous
streptomycin resistant
mutant of EFC1
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EFC2 StrR

spontaneous

EFC2

(55)

F-18

(56)

EDL933

(54)

ATM161

(17)

streptomycin resistant
mutant of EFC2
F-18 StrR NalR

spontaneous
streptomycin and
nalidixic acid resistant
mutant of F-18

EDL933 StrR

spontaneous
streptomycin resistant
mutant of EDL933

ATM161

host for pUT, which
contains the miniTn5 Km transposon,
resistant to kanamycin

124

Table 2. PCR primer sequences for amplifying mutant genes containing mini-Tn5 Km
insertions.
gene
gdh
A

Primer 1: 5′→3′
GATGGTCGAGTGGCAGATTAC

Primer 2: 5′→3′
CAGAGGCTACTCAATGGCTT
AC

gnd

GTTGGTTAAATCAGATTAATCCAGCC

CAACAGATCGGCGTAGTCG

pykF CTGTAGCAATTGAGCGATGAT G

ATCAGGGCGCTTCGATATAC

sdhA CCGTTCCCATACCGTTTCTG

TTTCACCGGATCAACGTGAG

zwf

GAGAATGACATGGCGGTAAC

CCGGTAAAATAACCATAAAGGATAA
GC
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Table 3. Free amino acid composition of 50-fold concentrated E. coli MG1655 and E.
coli CFT073 supernatants and human urine (µM).
c
E. coli MG1655
E. coli CFT073
Human Urine
b
b
Supernatant
Supernatant
alanine
353
383
3350
arginine
205
aspartic acid
22
cysteine
1110
glutamic acid
360
848
glycine
11
86
21200
histidine
9470
isoleucine
90
170
478
leucine
56
149
382
lysine
7472
4059
4480
methionine
59
37
171
phenylalanine
99
187
626
proline
144
116
serine
64
70
4000
threonine
201
461
2430
tryptophan
146
312
tyrosine
13
52
1060
valine
229
748
349
a
b
amino acids not listed are not present in the preparations; see Materials and Methods

Amino Acid

c

a

for details; average of 39 women, reference (26).
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Table 4. E. coli CFT073 persister cells relative to persister cells for other E. coli strains.
E. coli strain

# of
experiments

% persister
a
cells ± SEM

CFT073
persister cells
a
relative to:
1.65
0.23
1.45
0.21
1160

P value

CFT073
7
0.71 ± 0.19
0.34 ± 0.18
CFT073 gnd
2
0.44
2.37 ± 0.18
CFT073 pykF
2
0.075
0.29
±
0.29
CFT073 zwf
2
0.43
2.64 ± 1.22
Nissle 1917
2
0.16
-4
2.80
x
10
±
True wildtype
2
0.025*
1.1 x 10-4
CFT073
a
% persister cells was calculated by dividing the viable count at 24 h by the viable count
at time zero times 100. The value for E. coli CFT073 persister cells relative to a specific
E. coli strain is calculated by dividing the % persister cells at 24 h generated by E. coli
CFT073 in the experiments listed for the specific strain by the % persister cells at 24 h
generated by that specific strain in those experiments. *P < 0.05 using the two-tailed
Student t test is considered to be statistically significant.
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Legends to the Figures
Fig. 1. E. coli CFT073 quiescence on glucose plates. A 0.2% glucose plate was seeded
with 105 CFU of E. coli CFT073 (see Materials and Methods). (A), 60 min after seeding
the plate, a colony of E. coli MG1655, grown on a glucose plate, was toothpicked to the
plate seeded with E. coli CFT073, which was then incubated at 37°C for 24 h; (B), the
same plate, incubated for 48 h. Note that E. coli CFT073 only grows around the
toothpicked E. coli MG1655. Although not shown, E. coli Nissle 1917 undergoes
quiescence on glucose plates identically.
Fig. 2. E. coli CFT073 non-quiescence on glycerol, ribose, and xylose plates. 0.2%
glucose, glycerol, ribose, and xylose plates were seeded with 105 CFU of E. coli CFT073
grown overnight in liquid M9 minimal medium containing their respective sugars (0.4%).
60 min after seeding the plates, a colony of E. coli MG1655, grown on a glucose plate,
was toothpicked to the glucose plate. Plates were incubated at 37°C for 24h. (A),
glycerol plate; (B), ribose plate; (C), xylose plate; (D), glucose plate.
Fig. 3. Prevention of quiescence by human urine and amino acids. 0.2% glucose plates
were seeded with 105 CFU of E. coli CFT073 and 5 µl of the following mixtures were
spotted onto the plates. (A), 50-fold concentrated E. coli MG1655 culture supernatant;
(B), amino acid cocktail mimicking amino acid concentrations in the 50-fold
concentrated E. coli MG1655 culture supernatant; (C), human urine; (D), amino acid
cocktail mimicking amino acid concentrations in human urine (Table 3); (E), lysine,
methionine, tyrosine (1.0 mM each); (F), lysine and methionine (1.0 mM each); (G),
lysine and tyrosine (1.0 mM each); (H), methionine and tyrosine (1.0 mM each). Plates
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were incubated at 37°C for 24h. Although not shown, results for E. coli Nissle 1917
were essentially identical.

Fig. 4. E. coli CFT073 and E. coli MG1655 persistence. Cultures were grown overnight
in
0.4 % glucose M9 minimal medium as described in Material and Methods. Persister cell
assays were performed as described in Materials and Methods. (▲), E. coli CFT073; (●),
E. coli CFT073 plus ampicillin; (♦), E. coli MG1655; (■), E. coli MG1655 plus
ampicillin. Bars representing standard errors of the log10 means of CFU per ml for 2
independent experiments are presented for each time point. At 24 h the approximate
1000-fold difference between E. coli CFT073 persisters in the presence of ampicillin and
E. coli MG1655 persisters in the presence of ampicillin is statistically significant (P =
0.0052).
Fig. 5. E. coli CFT073 persistence in the presence of amino acids. Cultures were grown
in 0.4 % glucose M9 minimal medium as described in Material and Methods and diluted
20-fold into 0.2 % glucose M9 minimal medium either containing or lacking a mixture of
the 20 standard L-amino acids, each at 100 µg/ml and containing or lacking ampicillin
(100 µg/ml). (♦), E. coli CFT073; (■), E. coli CFT073 plus ampicillin; (▲), E. coli
CFT073 plus amino acids; (●), E. coli CFT073 plus amino acids plus ampicillin. Bars
representing standard errors of the log10 means of CFU per ml for 2 independent
experiments are presented for each time point. At 6 h and 24 h the approximate 100-fold
differences between E. coli CFT073 persisters in the presence of ampicillin and E. coli
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MG1655 persisters in the presence of ampicillin are statistically significant (P = 0.002
and P = 0.05 respectively).
Fig. 6. Diagram of E. coli central carbon metabolism. Arrows indicate the
physiological directions of the reactions. Genes encoding the enzymes for each reaction
are listed beside each reaction. Mini-Tn5 Km insertions in E. coli CFT073 genes that
result in non-quiescence on glucose plates are circled.
Fig. 7. E. coli CFT073 sdhA persistence. Cultures were grown overnight in 0.4 %
glucose M9 minimal medium and persister cell assays were performed as described in
Materials and Methods. (♦), E. coli CFT073; (■), E. coli CFT073 plus ampicillin; (▲), E.
coli CFT073 sdhA; (●), E. coli CFT073 sdhA plus ampicillin. Bars representing standard
errors of the log10 means of CFU per ml for 4 independent experiments are presented for
each time point. At 24 h the approximate 2000-fold difference between E. coli CFT073
persisters in the presence of ampicillin and E. coli CFT073 sdhA persisters in the
presence of ampicillin is statistically significant (P < 0.001).
Fig. 8. E. coli CFT073 gdhA persistence. Cultures were grown overnight in 0.4 %
glucose M9 minimal medium and persister cell assays were performed as described in
Materials and Methods. (♦), E. coli CFT073; (■), E. coli CFT073 plus ampicillin; (▲), E.
coli CFT073 gdhA; (●), E. coli CFT073 gdhA plus ampicillin. Bars representing standard
errors of the log10 means of CFU per ml for 3 independent experiments are presented for
each time point. At 24 h the approximate 2000-fold difference between E. coli CFT073
persisters in the presence of ampicillin and E. coli CFT073 gdhA persisters in the
presence of ampicillin is statistically significant (P < 0.001).
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Fig. 9. E. coli CFT073 sdhA persistence in the presence of fumarate. Cultures were
grown overnight in 0.4 % glucose M9 minimal medium containing or lacking disodium
fumarate (200 µg/ml), diluted 20-fold into 0.2% glucose M9 minimal medium containing
or lacking fumarate, and persister cell assays were performed as described in Materials
and Methods. (▲), E. coli CFT073 sdhA; (●), E. coli CFT073 sdhA plus ampicillin; (♦),
E. coli CFT073 sdhA plus fumarate; (■), E. coli CFT073 sdhA plus fumarate plus
ampicillin. Bars representing standard errors of the log10 means of CFU per ml for 2
independent experiments are presented for each time point. At 6 h and 24 h the
differences between E. coli CFT073 sdhA persisters in the presence and absence of
fumarate are statistically significant (P = 0.013 and P = 0.046 respectively).
Fig. 10. Rescue of E. coli CFT073 sdhA quiescence by fumarate. E. coli CFT073 sdhA
was grown overnight in 0.4 % glucose M9 minimal medium and 105 CFU were seeded on
(A), 0.2% glucose plates containing disodium fumarate (200 µg/ml) or (B), 0.2% glucose
plates. One hour later, 5 µl of a mixture of 1.0 mM lysine, 1.0 mM methionine, and 1.0
mM tyrosine was spotted to each plate. Plates were incubated at 37°C for 24 h.
Fig. 11. Quiescence of the E. coli CFT073 original clinical isolate on glucose plates. 0.2%
glucose plates were seeded with 105 CFU of the E. coli CFT073 original clinical isolate and
5 µl of the following mixtures (1.0 mM of each amino acid) were spotted onto the plates.
(A), lysine, methionine, tyrosine; (B), lysine and methionine; (C), lysine and tyrosine;
(D), methionine and tyrosine. Plates were incubated at 37°C for 24h.
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CHAPTER 5
This manuscript is formatted for publication in Scientific Reports. The formatting
follows the guidelines set forth by the journal.
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Abstract
Urinary tract infections (UTIs) caused by Escherichia coli create a large burden on
healthcare and frequently cause recurrent infections. Contributing to the success of E.
coli as an uropathogenic bacterium is its ability to form quiescent intracellular reservoirs
in bladder cells and persistence after antibiotic treatment. Cranberry juice and related
products have been used extensively in the treatment and prevention of UTIs with
varying degrees of benefit reported in the literature. In this study, cranberry
oligosaccharides and related compounds were found to both reduce the fraction of
persister cells formed and inhibit quiescence in the uropathogenic strain, CFT073. This
is the first report detailing components of cranberry juice with the ability to modulate
these important physiological aspects of uropathogenic E. coli, and further studies
investigating cranberry juice should be keen to include oligosaccharides as part of the
‘active’ cocktail of chemical compounds.
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Bacterial urinary tract infections (UTIs) are among the most common infections
in the world affecting up to 150 million people each year.1 In the US alone, it is estimated
that the total societal cost burden of UTIs is $3.5 billion each year.2 Women are one of
the most important at risk demographics with a lifetime prevalence of over 50% and an
estimated recurrence of about 25%.3 While UTIs are commonly mild and curable,
recurrent infections can require continuous antibiotic prophylaxis for prevention which
can lead to adverse events such as colitis, the development of antibiotic resistant UTIs, or
the development of complicated UTIs.2-4
Uropathogenic Escherichia coli (UPEC) is the causative pathogen in the majority
of UTIs, with estimates ranging anywhere from 65-90% of cases.2,4-6 When UPEC is the
identified pathogen in a recurrent UTI, the original infecting UPEC strain is responsible
for the recurrence 77% of the time.7 While the mechanism of recurrence is not fully
understood, it is thought that intracellular biofilm-like communities (IBCs) and quiescent
intracellular reservoirs (QIRs) contribute significantly to recurrent UTIs.8-10 During acute
infection, UPEC are able to adhere to, invade, and replicate inside of superficial bladder
cells, forming IBCs.6,10 As the infection progresses, UPEC infection of the urothelial
transitional cells can lead to establishment of QIRs which can remain viable for months
intracellularly.6,9,11 Importantly, it is also thought that QIRs may not be affected by
antibiotics, contributing to treatment failures and recurrence.8,10 Upon exfoliation of the
bladder epithelial cells containing the QIRs, the UPEC would be re-exposed to the urine
and could cause recurrent infection.6 It was also shown in vitro that the amino acid
content of the urine is able to reverse quiescence in UPEC, and could serve as the
necessary signal for reinfection.12
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A similar physiologic state to quiescence in UPEC is bacterial persistence.13-16
Persister cells are a small subpopulation of bacteria in a dormant, non-dividing state
characterized by high antibiotic tolerance.13,14,16 Persistence differs from antibiotic
resistance in that upon regrowth of the persister cell fraction after initial antibiotic
treatment, the bacteria retains sensitivity to the antibiotic and can consistently form the
same persister cell fraction.17 Persister cells are strongly implicated in the pathogenesis of
chronic infections, including recurrent UTIs where persistence of UPEC has been
extensively studied.12,18-21 While proven to be different metabolically, quiescence and
persistence both likely contribute to the ability of UPEC to cause recurrent UTI and
treatment failures.12 Therapies aimed at preventing or reversing quiescence and
persistence could significantly reduce the burden of UPEC recurrent UTI.
Cranberry (Vaccinium macrocarpon) products have been extensively researched
for their role in the treatment and prevention of UTIs especially in UPEC and other
pathogens.22-27 While many studies have shown benefit, especially those completing in
vitro experiments, the current clinical role of cranberry products in UTIs is
controversial.22-26 Despite numerous completed studies, there is a lack of consistency in
the type of study, study demographic, and especially the cranberry products and these
inconsistencies can contribute to the conflicting evidence.23 Specifically, current
literature states that the major ‘active’ components are proanthocyanidins (PACs) with Atype linkages and fructose, both of which interfere with UPEC adherence to the
bladder.23,25,28 However, in a comprehensive Cochrane review of 24 clinical studies, only
five of the studies indicated a measurement of the amount of PACs in their tested
products (juice, concentrate, capsules, or tablets), displaying the shortcomings of much of
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the chemistry in the clinical trials completed thus far.23 With inconsistent standardization
of the cranberry chemistry, and inconsistent clinical evidence for its use in prevention of
UTIs, we sought to determine if there were other therapeutic targets that cranberry
chemistry could exploit to aid in the prevention of UTIs and recurrent UTIs, especially in
UPEC. With the hypothesized importance of IBCs and QIRs to the infection cycle and
recurrence of UTIs, as well as published studies detailing natural product compounds that
are able to sensitize persister cells to antibiotics,29-31 we hypothesized that compounds
from cranberry may be able to reduce persistence and/or quiescence in UPEC. In the
following study, we identify carbohydrate components from cranberry juice that are able
to prevent quiescence in UPEC. Additionally, another subset of small molecules from
cranberry juice significantly reduces the fraction of UPEC persister cells.

Results

Bioassay guided fractionation of active constituents from cranberry juice: A
pectinase (Klerzyme 150, DSM Food Specialties) degraded cranberry hull extract was
purified using C18 flash chromatography to afford three fractions: the 100% water
fraction, 15% MeOH fraction, and the 100% MeOH fraction. From previous work
completed by our lab, it was known that the 15% MeOH fraction (Cranf1b) was enriched
in oligosaccharides and was able to reduce biofilm formation in the UPEC CFT073.32
This fraction was further tested in our previously published CFT073 persister cell assay,12
and showed a greater than 3-log reduction in persister cells at 24 h at 1 mg/mL (0.1%
wt/vol) in the presence of ampicillin (0.1 mg/mL) when compared with ampicillin
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treatment alone (Figure 1). Using CFT073 persister cell reduction to guide purification,
we further purified Cranf1b using porous graphitized carbon (PGC) cartridges and
determined that the second fraction (entitled 10% PGC) was similarly able to reduce the
CFT073 persister cells more than 3 logs at a final concentration of 0.6 mg/mL (0.06%)
(Figure 2). The 10% PGC fraction was further purified by semipreparative HPLC and
analyzed using NMR and LC/MS to determine the chemical components of this fraction.
Structure elucidation of active constituents from cranberry juice: The 1H and HSQC
spectra of 10% PGC indicated that this fraction was enriched with oligosaccharides with
methoxy group at 3.70 ppm and an additional correlation at 6.00/112.04 ppm in HSQC
which together highly suggest the presence of a group of poly-galacturonic acid methyl
esters with at least one hydroxyl group reduced. Therefore, this fraction was further
fractionated using an amide column that provides superior separation of this class of
molecules. The same amide column and program was used for LC-MS analysis and
preparative purpose. Indeed, LC-MS chromatogram showed that the predominate ions
presented were poly-galacturonic acid methyl esters of various degrees of
polymerization. The most abundant ions were with one or two free carboxylic acids and
with one degree of unsaturation. Surprisingly saturated poly-galacturonic acid methyl
esters were minor ions in this fraction. Due to the ultra-high complexity of this fraction,
only two unsaturated poly-galacturonic acid methyl esters were fully purified. The two
pure unsaturated poly-galacturonic acid methyl esters were of 4-mer and 3-mer with one
free carboxylic acid (compounds 4 and 5, respectively). Due to the very limited quantity,
only 4 was fully characterized with NMR and tested in the biological assays. The 1H and
13

C NMR chemical shifts of 4 were listed in Table S1. Five spin systems were found in
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total and were registered to the four subunits (A, B, C, D, Figure 3) in the oligomer. Key
HMBC and NOESY correlations across glycosidic bond were shown in Figure 3. In
addition, HMBC correlation between carbonyl carbon on each unit and methyl group was
only found for subunit A, B and D, suggesting the free carboxylic acid was located on
subunit C. The ESI-TOF-MS/MS fragmentation with sequential neutral losses of 190 Da
in 4 was deduced as shown in (Figure 4) The dehydration at the 4- position on the
galacturonic acid opposite of the reducing end was very much likely due to the enzymatic
degradation during cranberry juice manufacturing to break down the insoluble pectic
polysaccharides. Unlike acid hydrolysis, some pectinase can selectively hydrolyze the
glycosidic bonds via eliminative cleavage and cause oxygen-aglycone bond breakage.
This eliminative cleavage generally occurs by the free carboxylate group because of its
strong electron withdrawing effect.33-35 Along with these unsaturated oligosaccharides,
three previously reported iridoid glucosides were also isolated and identified to be 6,7dihydromonotropein (1), deacetylasperulosidic acid (2) and monotropein (3) (Figure
S2).36-39 To the knowledge of the authors, this is the first identification of 2 from V.
macrocarpon.
Purified cranberry juice constituents and CFT073 quiescence: Using the compounds
purified from cranberry juice, we investigated whether or not the inhibition on CFT073
persister cells could also be demonstrated with quiescent CFT073. 100 μg spots of each
4, the 10% PGC fraction, mixed methyl galacturonic acid oligosaccharides fraction (AmF6), and 1-3 were tested in the previously published quiescence lawn overlay assay.12
The spot from the 4, the 10% PGC fraction, and the mixed methyl galacturonic acid
oligosaccharides fraction (Am-F6) all showed regrowth, thus demonstrating inhibition of
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quiescence (Figure 5). It was notable that the growth with the pure 4 was not as dense as
with the other active samples. Each of the tested iridoids (1-3) did not show an inhibition
of quiescence.

Discussion

Despite years of practice, clinical trials, and bench research, the narrative surrounding the
benefits of cranberry juice in UTIs is not fully understood. There are many explanations
attempting to justify its use-from the increased acidity of the juice to the anti-adhesive
compounds such as PACs-but clinical evidence fails to fully support the scientificallyderived benefits.3,23 The under-studied oligosaccharide components of cranberry juice
discussed in this manuscript comprise a previously undiscovered benefit, though we have
seen anti-biofilm effects with cranberry oligosaccharides previously.32 Pectic
oligosaccharides formed in the presence of a juice-making pectinase are able to reduce
persistence in UPEC. Over a 1000-fold decrease in persistent UPEC could have a
tremendous effect on treatment outcomes as there would be less cells ‘avoiding’ the
antibiotic treatment through persistence. It is important to consider that any positive
effects of cranberry oligosaccharides on persister cells could only be appreciated in the
presence of antibiotics, so this effect could be defined as a ‘treatment’ benefit. However,
the inhibition of quiescence in UPEC seen with the cranberry oligosaccharides could
directly hinder the ability of the UPEC to establish a QIR, thereby reducing the likelihood
of a recurrent UTI.6 Inhibition of quiescence does not require antibiotics and could
therefore be loosely interpreted as a ‘preventative’ effect on recurrent UTIs. While the in
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vitro effects described in this manuscript are distinct from one another, it is important to
remember that persistence and quiescence are similar biological states. It is beyond the
scope of this manuscript to determine if the physiologic change in UPEC associated with
cranberry oligosaccharides is consistent between the anti-persistence and anti-quiescent
effects. Investigations into the biological manifestations of reducing persistence and
quiescence in UPEC are necessary next experiments to further understand the beneficial
role of these oligosaccharides.
While the completed experiments are preliminary, the results strongly suggest that
cranberry oligosaccharides formed during the juice-making process have the potential to
benefit sufferers of UTIs caused by E. coli and especially in those suffering from
recurrent E. coli UTIs. It is rational to surmise that the full benefit of cranberry juice may
not be realized with one class of chemical compounds, but multiple. From our previous
chemical purification of oligosaccharides, we know that enrichment of the
oligosaccharides is nearly synonymous with removal of phenolic compounds, including
the important type A PACs.32 One could assume that a phenolic-enriched (or PACs
enriched) fraction might be similarly depleted of oligosaccharides, including those
identified in this study. If the ultimate goal is to understand what the full benefit of
cranberry juice components are in UTIs, more careful chemistry is needed to assure that
the preparations tested include the right compounds, in sufficient quantity. Exhaustive
reviews of the clinical data show clearly that inconsistencies in the chemical
standardization are rampant in the literature.23 Using the juice as the supplement is the
obvious answer to including all the components, but there would still need to be clarity
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on how much of the juice is necessary to drink, especially in the case of the
oligosaccharide content.
There is still much work left to do to determine if cranberry oligosaccharides can
have a meaningful effect on the treatment or prevention of UPEC UTIs.
Pharmacokinetic, in vivo modeling, and mechanistic experiments are necessary to
elucidate the answer. While these gaps in the research are significant, the current data
invites a new class of compounds to be considered as part of the ‘active’ component of
cranberry juice. We strongly feel that chemical preparations of cranberry meant to yield
benefits in UTIs should not exclude oligosaccharides or they may be missing a crucial
component to cranberry’s anti-infective cocktail.

Methods

General experimental procedures: NMR experiments were conducted using an Agilent
NMRS 500 MHz spectrometer in D2O (99.99%, Sigma-Aldrich) at 25 °C. LC/MS
analysis was performed on a Shimadzu Prominence UFLC system coupled to an AB
Sciex Qtrap 4500 mass spectrometer with electrospray ionization source in the negative
ion mode. High Resolution Electrospray ionization mass spectra (HR-MS) were acquired
using an AB Sciex TripleTOF 4600 spectrometer in the negative ion mode. Flash
chromatography was completed with a Combiflash Rf200 equipped with a 100 g C18
RediSepRf High Performance Gold column (Teledyne ISCO). HPLC purification
experiments were performed on a Shimadzu Prominence i-series HPLC.
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Purification of cranberry compounds: Cranberry hulls were degraded with pectinase
(Klerzyme 150, DSM Food Specialties) and fractionated as previously described with
modifications.32 Briefly, 2 g of the cranberry pectinase treated powder was dissolved in
20 ml distilled water and purified using flash chromatography. The column was eluted
sequentially with 500 ml DI water, 500 ml 15% methanol/water and 500 ml methanol.
Fractions from each gradient were individually pooled and lyophilized to obtain three
major fractions, Cranf1W (761 mg, 38.1%) eluted with 100% DI water, Cranf1b (476
mg, 23.8%) eluted with 15% methanol/water, and Cranf1M (562 mg, 28.1%) eluted with
100% methanol. The Cranf1b was then subject to purification using a porous graphitized
carbon (PGC) cartridge (1 g, Thermofisher Scientific). The PGC cartridge was first
conditioned by eluting with 50% ACN/water and then equilibrated with DI water. For
each round of PGC purification, 40 mg of Cranf1b was dissolved in 2 mL of DI water,
loaded onto the PGC cartridge, and eluted sequentially with 18 mL DI water, 12 mL 10%
ACN/water (+0.1% TFA), and 30% ACN/water (+0.1% TFA). Fractions were
individually pooled and dried in vacuo to obtain three major fractions: 100% water PGC,
10% PGC, and 30% PGC. The 10% PGC fraction was then purified using HPLC and a
TOSOH Tskgel Amide-80 HR (4.6 × 250 mm, 5 μm) (TOSOH Bioscience) at 1 mL/min
and 35°C. The column was initially eluted with 80% ACN/water (+0.1% formic acid) for
2 min, followed by a linear gradient to 40% ACN/water (+0.1% formic acid) over 30 min
and held for 5 min. This afforded six fractions (Figure 3): Am-F1 (2.5-8 min), Am-F2
(peak at 8.6 min, mixture of 1 and 2), Am-F3 (9 min, 3), Am-F4 (split peak at 12 min),
Am-F5 (split peak at 14 min, 4), and Am-F6 (15-25 min). The wavelength of UV
absorbance was set at 235 nm for optimal monitoring of dehydro-poly-galacturonic acids.
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Am-F2 was further purified by semipreparative HPLC with a Waters Xbridge C18
column (4.6 × 250 mm, 5 μm) at 1 mL/min 35°C with isocratic 5% MeOH/water (+0.1%
Formic acid) for 20 min to afford pure 1 and 2 (Figure 4).
Structure elucidation of purified compounds: The LC/MS analysis was performed on
the same Amide-80 column and same HPLC program as in “Purification of cranberry
compounds.” The mass spectrometer was operated in negative mode and ions from m/z
200 to m/z 2000 were scanned. Compounds 1-4 were subject to one and two dimensional
NMR experiments to determine structures. Additionally, molecular weights were
determined for pure compounds using HRMS. For necessary MS/MS experiments,
collision energy was set to 70.
Bacterial strains and cultivation: E. coli CFT073 was obtained from a cryo stock at the
lab of P.S.C. and stored at -80°C in a 1:1 mixture of LB broth and 50% glycerol by
volume. LB broth and LB agar were used for routine cultivation. Liquid M9 minimal
media was prepared as before,12 and M9 minimal media agar plates were prepared with
1.5% noble agar to avoid impurities present in bacteriological agar.
Persister cell viability assay: The procedure for this assay closely follows a published
protocol.12 In general, CFT073 was streaked from cryo stocks onto LB agar plates and
incubated overnight at 37°C. A loopful of cells from the plate was added to 10 mL 0.4%
glucose M9 minimal media in a 125 mL culture flask and incubated overnight at 37°C
and 200 rpm. Cultures were diluted in fresh 0.2% glucose M9 minimal media to an
optical density (OD600) of 0.1 (~108 CFU/mL) and grown in the presence of ampicillin
sodium (0.1 mg/mL) to generate persister fractions. The cultures were incubated shaking
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(200 rpm) at 37°C and viable counts were measured at 0, 4, and 24 hours by plating on
LB media.
Quiescence lawn assay: The procedure for this assay follows closely follows a published
protocol.12 In general, overnight cultures of CFT073 were prepared in 0.4% glucose M9
minimal media as described in “Persister cell viability assay.” Bacteria from this culture
were diluted to a final concentration of 105 CFU in 4 mL of liquid overlay media (0.2%
glucose M9 minimal media with 0.9% noble agar at 45°C). Each 4 mL overlay inoculum
was poured over a prewarmed (37°C) 0.2% glucose M9 minimal media agar plate
immediately after inoculation. These plates were allowed to solidify at room temperature
with lids slightly ajar. Test solutions or bacteria were added to the overlay media and
allowed to dry before incubating the plate upside down at 37°C for 24 or 48 hours as
indicated. No growth of E. coli in the overlay was considered to be quiescence if it was
able to be reversed with the positive control (3 co-spots of 5 μL of each tyrosine, lysine,
and methionine at 0.1 mg/mL).
Statistics: Persister assays were completed in triplicate and compared using a two-tailed
student’s t test. P-values < 0.05 were considered statistically significant.
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Figure 1: Persister cell viability assay using Cranf1b fraction as the test sample. **statistically significant, A- ampicillin.
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10% PGC Fraction Persister Assay
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Figure 2: Persister cell viability assay using 10% PGC fraction as test sample. **statistically significant, A- ampicillin.
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Figure 3: Subunits of 4. Key HMBC correlations are designated with single-headed
arrows and key NOESY correlations are designated by double-headed, dotted arrows.
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Figure 4: ESI-TOF MS-MS of 4. Structure fragments are designated with the
corresponding fragment ions.
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Figure 5: Representative quiescence overlay assay plates. Upper image: AA- amino acid
mixture, positive control; M9- negative control. Lower image: Am-F5- 4; Am-F6mixture of methylated galacturonic acid oligosaccharides; 10% PGC- fraction described
in text.
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Figure 6: Amide-80 HPLC chromatogram of 10% PGC.
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Figure 7: C18 Reverse-phase HPLC chromatogram of 1 and 2 mixture.
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Figure 8: LC-MS analysis of 10% PGC. From top to bottom: Total ion chromatogram;
Extract ions of m/z 391 and m/z 389; Extract ions for saturated poly-galacturonic acid
methyl esters (DP 3-8); Extract ions for unsaturated poly-galacturonic acid methyl esters
(DP 3-8), single free carboxylic acid; Extract ions for unsaturated poly-galacturonic acid
methyl esters (DP 3-8), double free carboxylic acids.
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CHAPTER 6
Perspective
The current paradigm for treating bacterial infections is about identifying the
causative pathogen, and choosing an antibiotic that is capable of killing or inhibiting the
growth of that particular pathogen. This is the perfect system for developing
antimicrobial resistance because these antibiotics that kill or inhibit growth are the exact
types of environmental stressors that a bacterium would need to develop a mechanism for
circumventing in order to survive. As such, bacterial resistance to antibiotics is growing
at an alarming rate and actions are urgently needed to avert this impending pandemic.
The identification of new antibacterial molecules and the development of these
chemical compounds into medicines remains a crucial component in our arms race
against bacteria. Declining participation in antibiotic research from the pharmaceutical
industry does not help this problem. With fewer resources and time at the disposal of
researchers, we must choose wisely where we search for these new antibacterial agents
that we desperately need. Investigating natural products (especially those from
microorganisms) has been by far the most successful method for finding molecules that
become antibiotic drugs, and this remains a viable resource going forward. Importantly,
while natural products research is thought of as a ‘classical’ research method, it has been
decades since the development of natural antibacterial compounds was commonplace in
industry and there have been thousands of antibacterial compounds isolated and
published since. In addition, with new frontiers such as microorganisms from the marine
environment to explore, the microbial natural resource of antibacterial agents remains
largely undiscovered.
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Continuing to fight fire with fire- that is killing bacteria with antibiotics until they
develop resistance to them- is a never-ending battle. In order to fully sustain the
monumental achievement of antibiotics, we must target the very mechanisms of
resistance and the characteristics of bacteria that make them pathogenic to find new ways
to treat infections. Efflux pumps and the subsequent efflux pump inhibitors are one good
example of a way to reclaim antibiotics that are losing their potency. Other molecules
have shown utility as drugs to re-sensitize resistant pathogens to antibiotics.
Additionally, targeting mechanisms of pathogenicity such as persistence and quiescence
in this manuscript, or other characteristics like biofilms and quorum sensing are viable
avenues towards stopping infections without stimulating resistance. Also beyond
antibacterial compounds, we can learn new ways to treat infections from simple things
like cranberry juice. Oligosaccharides with no antibacterial effect whatsoever through a
different biological lens look particularly important to the juice’s effects in UTIs. We
must increase our understanding of how and why the pathogens are causing infections in
order to find the best ways of treating them.
I will end this dissertation with a few broadly reaching statements and some
thought provoking questions from working in this particular area of research:
Preventing an infection is far better than having to treat it, but bacteria are such a
huge part of human life, it seems no amount of standardized precautions would stop
infections from happening all together, that being said, we must have viable ways to treat
them or we face losing vital aspects of medicine that are taken for granted. Currently,
research into developing truly new ways to treat bacterial infections is a bare industrial
landscape. Who is going to pay for clinical trials of non-antibiotic agents for infections if
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the industry will not? Or better yet, what do we have to change in our health care system
to incentivize developing antibiotics and similar agents? Perhaps we as a society are not
yet ready to make these changes and commit to whatever it takes to preserve our
antibacterial luxury. Or maybe the data is not compelling enough to force change in this
developmental landscape. What will be the cost of failing to develop new antibiotics for
5 more years? What about 10 or 20? I shudder to think about pan-drug resistant
Acinetobacter baumannii colonizing the majority of our hospitals. Do we really know
how long it will take for something like that to happen? If we only lose 23,000 lives in
this country to MDR bacteria per year now, how many lives must be lost per year for the
general public to become aware of this issue? I sincerely hope that the problem of
antimicrobial resistance will be solved quietly, but I fear that the noise must become
louder to draw the attention necessary to prevent the impending post-antibiotic era.
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Additional Results
1.1

Bioassay Screening of B. denitrificans Extract
Extract from isolate B158 reduced the MIC of erythromycin >4-fold when tested

against E. coli MDR strains MG1655 ΔBC/pABM, and MG1655 ΔBC/pXYM according
to previously published methods.[1] These strains overexpress two Resistance
Nodulation cell Division (RND) transporters involved in antibiotic resistance. Bioassayguided fractionation of the B158 extract resulted in the isolation of 1 with an MIC
between 0.63 – 1.25 μg/mL against E. coli MDR strains MG1655 ΔBC/pABM, and
MG1655 ΔBC/pXYM.
1.2

Biofilm Formation Assay for Characterization of A. baumannii Strains
Quantification of biofilm formation was conducted using a modified microtiter

plate assay [2-4] previously described by Song et al.[5] Briefly, strains were grown
overnight on Tryptic Soy Agar (TSA, Becton–Dickinson, Sparks, MD, USA). Tryptic
Soy Broth (TSB; Becton–Dickinson, Sparks, MD, USA) supplemented with 1% dextrose
(for total dextrose concentration of 1.25%) was used to optimize biofilm production in
the biofilm assay. A 0.5 McFarland standard of overnight growth of test isolates was
diluted into TSB. The inoculated medium was dispensed into wells of sterile non-tissue
culture treated flat-bottom 96-well polystyrene plates (Costar no. 3370; Corning Inc.,
Corning, NY, USA). Plates were incubated on a shaker at 37 °C. After 24 h of biofilm
development, broth was removed and replaced with fresh TSB and incubated at 37 °C for
an additional 24 h. The solution was then removed and plates were carefully rinsed three
times with sterile water to remove planktonic bacteria. Adherent bacteria were dried
overnight and stained for 15 min with 0.1% crystal violet solution. The crystal violet was
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then resolubilized in 33% glacial acetic acid and the optical density (OD) of stained
adherent bacterial films was read at 570 nm using a spectrophotometer (ELX800, Biotek,
Winooski, VT). The OD readings of bacterial films were categorized into non-adherent,
weak, moderate, and strong based on previously described methods by Stepanovic et
al.[6] Isolate L1051 was used as a negative control strain. Experiments were carried out
in quadruplicate. OD readings were averaged, and standard deviations were calculated for
each isolate.[2,4]
1.3

Isolation and Dereplication of Additional Compounds from B. denitrificans B158
Briefly, 1152.4 mg of extract was applied to a silica gel column (40-60 µm, 60Å)

and eluted with a step-gradient of isooctane, (4:1) isooctane/ethylacetate (EtOAc), (3:2)
isooctane/EtOAc, (2:3) isooctane/EtOAc, (1:4) isooctane/EtOAc, EtOAc, (1:1)
EtOAc/MeOH, and 100% MeOH, yielding eight fractions. Bacterial susceptibility testing
in the INT assay indicated activity to be localized to the EtOAc elution. The active
fraction totaling was separated further into 96-deep well plates by semipreparative HPLC
using an Agilent 1200 series HPLC and a Phenomenex Luna® 5 µm C18 (2) 100 Å, LC
column (250 x 10 mm) as the stationary phase, heated to 30 °C and a gradient of water
and MeCN with a flow rate of 4 mL/min. All solvents were acidified with 0.1% FA.
Contents of the 96-deep well plate were dried down and tested in the INT assay, which
resulted in identifying three wells (E7, F7, and G7) eluting at 35:65 water/MeCN were
active. Contents of wells E7, F7, and G7 were combined and separated further into a 96deep well plate by semipreparative HPLC using an Agilent 1200 series HPLC and a
Phenomenex Luna® 5 µm C18 (2) 100 Å, LC column (250 x 10 mm) as the stationary
phase, heated to 30 °C and a gradient of water and MeCN with a flow rate of 4 mL/min.
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All solvents were acidified with 0.1% FA. The activity was found to be contained in a
single well (H10) eluting at 22.8 min corresponding to 5:95 water/MeCN visualized by a
single sharp peak at 276 nm. The contents of well H10 underwent an additional round of
HPLC purification using the above HPLC column, flow rate, but with starting conditions
of 1:1 water/MeCN. INT activity testing indicated a well resolved peak with minor
activity eluting at 4.5 min in 1:1 water/MeCN to contain all of the activity and totaling
2.6 mg of pure 11 as an amorphous yellow powder.
Structure elucidation efforts of 11 were pursued. An [M+H]+ ion of 243.0879
using HRESIMS indicated a molecular formula of C12H10N4O2. Examination of the 1H
NMR displayed two singlet methyl groups (δH 2.46, 3H, and δH 2.49, 3H) and two singlet
aromatic protons (δH 7.70, 1H and δH 7.91, 1H). These molecular features along with the
molecular formula strongly suggested the known microbial metabolite, 7,8dimethylalloxazine or lumichrome. This was further confirmed by NMR comparison to
literature [7] and LC/MS comparison (data not shown) to an authentic standard of
lumichrome (Cat. 103217, Sigma-Aldrich). A total of 2.6 mg of compound 11 was
isolated from 1152.4 mg of extract from 9 L of microbial culture.
Compound 12 was purified from the 96-deep well plate fractions H8, A9, B9,
totaling 25.1 mg, and had minor activity when tested in the INT assay. The 25.1 mg
fraction containing wells H8, A9, B9 was further separated by semipreparative HPLC
(Shimadzu Prominence-i LC-2030C). Compound 12 eluted at 15.7 min from the
following method: 0 to 4 min, 30% MeOH in aqueous 0.1% FA; 4 to 24 min, gradient
from 30% MeOH in aqueous 0.1% FA to 70% MeOH in aqueous 0.1% FA. This
afforded 12 as a white amorphous powder. The molecular formula was determined to be
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C10H8N2O2 using HRESIMS (m/z 187.0531 [M-H]-) and NMR. 1H-NMR indicated the
presence of a 1,2 substituted benzene ring based on resonances at δH 7.25 (m, 2H, H-5
and H-6), 7.53 (dd, 1H, H-7, J = 5.7, 2.2), and 8.22 (dd, 1H, H-4, J = 5.6, 2.5). In
addition, a singlet at δH 8.68 (1H, H-2) and MS/MS fragmentation experiments showing a
strong fragment at m/z 116 indicated that the aromatic protons were part of an indole
subunit (data not included). Using our molecular formula and the indole substructure, 12
was dereplicated as (1H-indol-3-yl) oxoacetamide by comparison of 1H and 13C-NMR to
published data (Table S1) [8]. A total of 25.1 mg of 12 was isolated from 18.2 g of
extract representing 118.5 L of microbial culture. Testing in bacterial susceptibility
assays indicates 12 has antibiotic-like properties against E. coli MDR strains MG1655
ΔBC/pABM, and MG1655 ΔBC/pXYM resulting in a reduction of 50% growth at 150
µg/mL.

177
Supplementary References
1.

Whalen, K.E.; Poulson-Ellestad, K.L.; Deering, R.W.; Rowley, D.C.; Mincer,
T.J., Enhancement of antibiotic activity against multidrug-resistant bacteria by the
efflux pump inhibitor 3,4-dibromopyrrole-2,5-dione isolated from a
Pseudoalteromonas sp. J Nat Prod 2015, 78, 402-412.

2.

Luther, M.K.; Arvanitis, M.; Mylonakis, E.; LaPlante, K.L., Activity of
daptomycin or linezolid in combination with rifampin or gentamicin against
biofilm-forming Enterococcus faecalis or E. faecium in an in vitro
pharmacodynamic model using simulated endocardial vegetations and an in vivo
survival assay using Galleria mellonella larvae. Antimicrob Agents Chemother
2014, 58, 4612-4620.

3.

LaPlante, K.L.; Mermel, L.A., In vitro activity of daptomycin and vancomycin
lock solutions on staphylococcal biofilms in a central venous catheter model.
Nephrol Dial Transplant 2007, 22, 2239-2246.

4.

LaPlante, K.L.; Mermel, L.A., In vitro activities of telavancin and vancomycin
against biofilm-producing Staphylococcus aureus, S. epidermidis, and
Enterococcus faecalis strains. Antimicrob Agents Chemother 2009, 53, 31663169.

5.

Song, J.Y.; Cheong, H.J.; Noh, J.Y.; Kim, W.J., In vitro comparison of antibiofilm effects against carbapenem-resistant Acinetobacter baumannii: imipenem,
colistin, tigecycline, rifampicin and combinations. Infect Chemother 2015, 47, 2732.

178
6.

Stepanović, S.; Vuković, D.; Dakić, I.; Savić, B.; Švabić-Vlahović, M., A
modified microtiter-plate test for quantification of staphylococcal biofilm
formation. J Microbiol Methods 2000, 40, 175-179.

7.

Ding, Z.G.; Zhao, J.Y.; Yang, P.W.; Li, M.G.; Huang, R.; Cui, X.L.; Wen, M.L.,
1H and 13C NMR assignments of eight nitrogen containing compounds from
Nocardia alba sp. nov (YIM 30243T). Magn Reson Chem 2009, 47, 366-370.

8.

Bao, B.; Zhang, P.; Lee, Y.; Hong, J.; Lee, C.O.; Jung, J.H., Monoindole alkaloids
from a marine sponge Spongosorites sp. Mar Drugs 2007, 5, 31-39.

179
Table S1: Comparison of 1H and 13C-NMR data of 12 and published (1H-indol-3-yl)
oxoacetamide. Chemical shifts are referenced to residual DMSO in DMSO-d6 at δH 2.50
and δC 39.5.
Isolated (1H-Indol-3yl) oxoacetamide (12)
position

δC, type

1
2
3
3a

138.2, CH
112.0, C
126.1, C

4

121.2, CH

5
6

122.4, CH
123.3, CH

7

112.5, CH

7a
8
9
NH2

136.3, C
182.9, C
166.0, C

δH, (J in Hz)
12.35, br s
8.68, s

8.22, dd
(5.6, 2.5)
7.25, m
7.25, m
7.53, dd
(5.7, 2.2)

Published (1H-Indol-3yl) oxoacetamide[1]
δC, type
138.1, CH
112.0, C
126.1, C

δH, (J in Hz)
12.19, br s
8.69, s

121.2, CH 8.22, d (6.0)
122.4, CH 7.25, t (6.0)
123.3, CH 7.25, t (6.0)
112.4, CH 7.52, d (6.0)
136.2, C
182.9, C
165.9, C

8.05 br s
7.69 br s

8.06 br s
7.69 br s
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Table S2: A. baumannii strain characteristics and resistance profiles.
A.
baumannii
strain

Source

L1051*

Clinical

L1222*

Blood

L1227

Blood

L1184

Urine

Biofilm
OD570
readings
0.19± 0.03
0.60± 0.12
0.94± 0.27
2.49± 0.17

Biofilm
Adherence**
0
1
2
3

* Multi-drug resistant organisms (MDRO)
**0-non-adherent, 1-weakly adherent, 2- moderately adherent, 3- strongly adherent
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Figure S1: Chemical structures of compounds 11 and 12.
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Figure S2: LC/MS comparison of isolated 1 to synthetic 1.
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Synthetic
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Figure S3: 1H NMR of isolated 1

Formic Acid
Impurity
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Figure S4: 1H NMR of synthesized 1
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Figure S5: 13C NMR of synthesized 1
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APPENDIX B
Supplemental Figures for Chapter 5

A (α-)

A (β-)

B

D

C

Position

δC
(ppm)

δH
(ppm)

δC
(ppm)

δH
(ppm)

δC
(ppm)

δH
(ppm)

δC
(ppm)

δH
(ppm)

δC
(ppm)

δH
(ppm)

1

92.3

5.25

96.3

4.55

100.5

4.88

100.0

4.80

99.5

5.04

2

67.7

3.71

71.2

3.38

67.8

3.62

68.0

3.57

69.8

3.65

3

68.0

3.93

67.8

3.69

67.8

3.92

68.4

3.83

65.5

4.23

4

78.8

4.36

78.5

4.31

78.2

4.39

79.0

4.43

111.8

6.00

5

69.7

4.72

73.1

4.40

70.4

4.99

71.2

4.64

140.6

6

170.5

7

52.8

169.6
3.70

52.8

170.7
3.70

52.8

Table S1: 13C and 1H NMR chemical shifts of 4.

175.0
3.70

164.0
52.8

3.71
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Figure S1: High resolution ESI-TOF-MS of 4.
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Figure S2: Structures of Iridoid glycosides 1-3.
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1

2

3

Position

δ C (ppm)

δ H (ppm)

δ C (ppm)

δ H (ppm)

δ C (ppm)

δ H (ppm)

1

94.8

5.42

97.3

5.04

93.7

5.44

3

152.0

7.40

148.3

7.08

144.4

7.47

4

112.0

5

32.0

2.84

44.8

2.89

38.3

3.43

6

29.4

1.93/1.57

80.8

4.41

137.9

6.10

7

34.9

1.70/1.56

128.5

5.75

137.2

5.56

8

81.8

9

45.4

2.24

45.9

2.94

44.1

2.56

10

67.6

3.47

59.8

4.22/4.17

66.6

3.54

11

191.3

1’

98.5

4.71

98.2

4.68

97.9

4.67

2’

72.5

3.17

72.6

3.22

72.8

3.18

3’

75.6

3.32

75.6

3.40

75.7

3.37

4’

69.4

3.31

69.1

3.31

69.5

3.29

5’

75.8

3.38

76.1

3.30

75.9

3.30

6’

60.5

3.80/3.62

60.4

3.78/3.60

60.6

3.80/3.62

Table S2. 13C and 1H NMR chemical shifts of 1, 2 and 3.
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Figure S3: 1H NMR spectrum of 10% PGC.
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Figure S4: HSQC spectrum of 10% PGC.
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Figure S5: 1H NMR spectrum of 4.
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Figure S6: 13C NMR spectrum of 4.
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Figure S7: COSY spectrum of 4.

195

Figure S8: TOCSY spectrum of 4.
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Figure S9: HSQC spectrum of 4.
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Figure S10: HMBC spectrum of 4.
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Figure S11: NOESY spectrum of 4.
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Figure S12: 1H NMR spectrum of 1.
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Figure S13: 13C NMR spectrum of 1.
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Figure S14: COSY spectrum of 1.
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Figure S15: TOCSY spectrum of 1.
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Figure S16: HSQC spectrum of 1.
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Figure S17: HMBC spectrum of 1.
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Figure S18: 1H spectrum of 2.
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Figure S19: COSY spectrum of 2.
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Figure S20: TOCSY spectrum of 2.
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Figure S21: HSQC spectrum of 2.
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Figure S22: 1H spectrum of 3.
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Figure S23: COSY spectrum of 3.
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Figure S24: TCOSY spectrum of 3.
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Figure S25: HSQC spectrum of 3.
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Figure S26: HR-MS of 1.
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Figure S27: HR-MS of 2.
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Figure S28: HR-MS of 3.

